

**New Mexico  
Public Schools Insurance Authority**



**Board of Directors Meeting  
December 7, 2023**



# New Mexico Public Schools Insurance Authority

## Board of Directors Meeting

### Board of Directors

Al Park, President, Governor Appointee  
Chris Parrino, Vice President, NM Association of School Business Officials  
Trish Ruiz, Secretary, Educational Entities at Large  
Denise Balderas, Governor Appointee  
Vicki Chavez, NM Superintendents Association  
Tim Crone, American Federation of Teachers NM  
Pauline Jaramillo, NM School Boards Association  
Bethany Jarrell, National Education Association - New Mexico  
K.T. Manis, Public Education Commission  
David Martinez, Jr., National Education Association - New Mexico  
Sammy J. Quintana, Governor Appointee

### In-Person & Virtual

#### **In-Person:**

Poms & Associates  
201 3rd Street, Suite 1400  
Albuquerque, New Mexico 87102

#### **Virtual:**

Please join my meeting from your computer, tablet, or smartphone.

<https://us02web.zoom.us/j/84408300040?pwd=WHh1Um5CczFlc0p5ZjVobUZjclhxZz09>

You can also dial in using your phone.

**United States: [+1 346 248 7799](tel:+13462487799)**

**Meeting ID: [844 0830 0040](tel:8440830040)**

**Passcode: [895193](tel:895193)**

**One Tap is also available on most mobile devices:**

**(clicking this link on a cell phone will dial in and enter all meeting information automatically)**

**[+13462487799,,84408300040#,,,895193#](tel:+13462487799,,84408300040#,,,895193#)**

Get the app now and be ready when your first meeting starts: <https://www.zoom.us/download>

**Thursday, December 07, 2023**

**9:00 a.m.**

### Agenda

**Draft**

1. Call to Order

A. Park

- |  |                              |
|--|------------------------------|
| 2. Roll Call   | C. Probst                    |
| 3. Introduction of Guests  | P. Sandoval                  |
| 4. Citizens to Address the Board <b>(Five-Minute Limit)</b>  | A. Park                      |
| 5. Approval of Agenda <b>(Action Item)</b>   | A. Park                      |
| 6. Approval of November 2023 Minutes <b>(Action Item)</b>  | A. Park                      |
| 7. Administrative Matters  |                              |
| A. Legislative Update  | P. Sandoval                  |
| B. Annual Retreat Discussion   | P. Sandoval                  |
| C. 2024 State and Local Government Benefits Association National Conference April 21-24, 2024, Louisville, Kentucky <b>(Action Item)</b> | P. Sandoval                  |
| D. 2024 Financial Disclosures  | P. Sandoval                  |
| 8. Financial Matters   |                              |
| A. Financial Reports for October 2023 <b>(Action Item)</b>   | P. Gonzales                  |
| B. Pay as Billed Penalty Exemption <b>(Action Item)</b>  | C. Probst                    |
| C. Request to Issue Request for Proposal for Investment Advisor Services <b>(Action Item)</b>  | P. Gonzales                  |
| D. Investment Performance Review for the Quarter Ended September 30, 2023  | E. Clark/ M. Sampson         |
| 9. Benefits Matters  |                              |
| A. Approval of Amendment to CVS Cost Saver Program and Rebate Guarantees <b>(Action Item)</b>  | D. Lauck/<br>M. Quintana     |
| B. Approval of Domestic Partner Resolution- Questa Independent School District <b>(Action Item)</b>                                      | C. Archuleta                 |
| C. Stop Loss Report on Claims and Reimbursement  | N. Patani                    |
| D. Request to Issue RFP for Third-Party Administrative Services for Enrollment, Eligibility, and Billing <b>(Action Item)</b>            | M. Quintana                  |
| E. Approval of Stop Loss Renewal <b>(Action Item)</b>  | N. Patani                    |
| F. Approval of United Concordia Dental Contract Amendment <b>(Action Item)</b>   | M. Quintana                  |
| G. SHAPE Report  | D. Donaldson/<br>S. Paralkar |
| H. Presentation of Benefits Analyst Statistics   | L. Martinez                  |
| I. Open/ Switch Enrollment Update  | K. Payanes                   |

- |   |                     |
|---|---------------------|
| J. Wellness Update  | C. Archuleta        |
| K. IBAC Update  | C. Archuleta        |
| 10. Risk Matters  |                     |
| A. 2023 New Mexico Safe School Summit Update  | P. Sandoval         |
| B. Request to Issue Request for Proposal for Risk Fund Actuarial Analysis, Statement of Actuarial Opinion, Rate Certification for NMPSIA's Self-Insured Workers' Compensation Exposure and Audit Reporting ( <b>Action Item</b> ) | P. Sandoval         |
| C. TPA Reports  |                     |
| 1. Property & Liability Monthly Claims Report   | S. Vanetsky         |
| 2. Property & Liability Large Losses  | S. Vanetsky         |
| 3. Workers' Compensation Monthly Claims Report  | J. Mayo             |
| 4. Workers' Compensation Large Losses   | J. Mayo             |
| D. Workers' Compensation Statistics   | R. Cangiolosi       |
| E. Anonymous Reporting Update   | J. Garcia           |
| F. Loss Prevention Update   | L. Vigil /J. Garcia |
| 11. General Discussion  | A. Park             |
| 12. Next Meeting Date and Location: Thursday, February 8, 2024<br>Location: Poms & Associates 201 3rd Street, Suite 1400 Albuquerque, New Mexico 87102, and a virtual option ( <b>Action Item</b> )                               | A. Park             |
| 13. Adjournment ( <b>Action Item</b> )  | A. Park             |

**NEW MEXICO PUBLIC SCHOOLS INSURANCE AUTHORITY  
BOARD OF DIRECTORS MEETING MINUTES**

**In-Person: Poms & Associates  
201 3rd Street, Suite 1400  
Albuquerque, NM 87102**

**Virtual: <https://meet.goto.com/659110589>  
Dial in +1 (312) 757-3121  
Access Code: 659-110-589**

**Thursday, November 02, 2023**

**DRAFT**

**1. Call to Order**

Mr. Chris Parrino, NMPSIA Board Vice-President, called the NMPSIA Board Meeting to order at 9:00 a.m. on Thursday, November 2, 2023.

**2. Roll Call**

Ms. Charlette Probst called roll.

**Board Members Present:**

Chris Parrino, Vice-President	In-Person
Trish Ruiz, Secretary	Virtual
Vicki Chavez	Virtual
Tim Crone	In-Person
Pauline Jaramillo	Virtual
Bethany Jarrell	Virtual- joined at 9:05
K.T. Manis	In-Person
David Martinez Jr.	Virtual
Sammy Quintana	In-Person

**Board Members Absent:**

Al Park, President  
Denise Balderas

**NMPSIA Staff Members Present:**

Patrick Sandoval, Executive Director	In-Person
Martha Quintana, Deputy Director	In-Person
Phillip Gonzales, Chief Financial Officer	In-Person
Charlette Probst, Financial/HR Manager	In-Person
Maria Lugo, Chief Procurement Officer	In-Person
Marlene Vigil, Financial Specialist	Virtual
Claudette Roybal, Risk Program Coordinator	Virtual
Cyndi Archuleta, Benefits/Wellness Operations Manager	Virtual- joined at 10:30
Kaylei Jones, Benefits/Wellness Program Coordinator	Virtual

Leslie Martinez, Benefits Analyst

Virtual

**Audience Present:**

Marsha Martinez	BAC	Virtual
Marlene Baca	BCBSNM	In-Person
Christopher Baker	BCBSNM	Virtual
Allison Trujillo	BCBSNM	Virtual
Lisa Sullivan	BCBSNM	In-Person
Lisa Gueverra	BCBSNM	Virtual
Samantha Mensay	BCBSNM	Virtual
Steve Vanetsky	CCMSI	In-Person
Jerry Mayo	CCMSI	In-Person
Rich Cangiolosi	CCMSI	In-Person
Courtney Barela	CCMSI	In-Person
Vanessa Devine	CCMSI	In-Person
Daniel Warner	Cigna	Virtual
Greg Moxie	Citizen	Virtual
Lara Clower	CVS	In-Person
David Lauck	CVS	In-Person
Sam Garcia	Davis Vision	In-Person
Simon Miller	DFA	In-Person
Stephanie Garcia	Delta Dental	Virtual
Kathy Payanes	Erisa Administrative Services	In-Person
Amy Bonal	Erisa Administrative Services	Virtual
Martin Esquivel	Esquivel & Howington	In-Person
Joseph Simon	Legislative Finance Committee	Virtual
David Poms	Poms & Associates	Virtual
Karen Mestas- Harris	Poms & Associates	Virtual
Erin Brannan	Poms & Associates	Virtual
Julie Garcia	Poms & Associates	In-Person
Larry Vigil	Poms & Associates	In-Person
Tamie Pargas	Poms & Associates	In-Person
Grant Banash	Poms & Associates	In-Person
Kevin McDonald	Poms & Associates	In-Person
Steve Valdez	Presbyterian	In-Person
Nura Patani	Segal	In-Person
Danielle Poore	The Standard	Virtual
Stephanie Anthony	United Concordia Dental	In-Person

**3. Introduction of Guests**

Mr. Patrick Sandoval, Executive Director of NMPSIA, introduced Mr. Rich Cangiolosi of CCMSI, Dr. Nura Patani with Segal, Mr. David Lauck and Ms. Laura Clower with CVS, Ms. Marlene Baca with BCBS, Mr. Ryan Bond with Cigna, and Ms. Marsha Martinez with Rio Rancho Public Schools, newly appointed to the Benefits Advisory Committee.

**4. Citizens to Address the Board (Five-Minute Limit)**

Mr. Greg Maxie thanked the board for their service and described the difficulties he has faced regarding treatment and claims related to a workman's compensation accident that occurred on August 11, 2023. Mr. Maxie advised he is now working with CCMSI to get the matter resolved and suggested some possible remedies to the issues he faced.

**5. Approval of Agenda (Action Item)**

Mr. Sandoval advised that there were no changes to the agenda.

**MOTION:** S. Quintana

**SECONDED:** T. Ruiz

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**6. Approval of October 2023 Minutes (Action Item)**

A motion was made to approve the October 2023 NMPSIA Board Minutes as presented.

**MOTION:** T. Crone

**SECONDED:** T. Ruiz

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes

Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**7. Administrative Matters**

**7. A. Legislative Update**

Mr. Sandoval reported that analysis of employee insurance contribution premium differences have started to be requested. NMPSIA is working with legislative agencies to provide the data requested for currently insured members and will continue to work with any other data requests received. Ms. Martha Quitana, Deputy Director of NMPSIA, added that NMPSIA benefits has two weeks left for open enrollment and will have a statistical update at the December meeting.

**8. Financial Matters**

**8. A. Approval of Financial Reports - August 2023 (Action Item)**

Mr. Phillip Gonzales, Chief Financial Officer NMPSIA, presented the Statement of Revenues and Expenditures for the period ending August 31, 2023, for the Employee Benefits Fund. Mr. Gonzales reported revenue of \$28,111,397.08 and expenses of \$36,900,304.12, which resulted in a loss of \$8,788,907.04 for August. Year-to-date revenues are \$57,675,583.09, and expenses were \$68,840,824.59, resulting in a loss of \$11,165,241.50.

Mr. Gonzales presented the Statement of Revenues and Expenditures for the period ending August 31, 2023, for the Risk Fund. Mr. Gonzales reported revenue of \$8,337,679.59 and expenses of \$12,002,845.13, which resulted in a loss of \$3,665,165.54 for August. Year-to-date revenues are \$17,343,661.10, and expenses were \$29,707,042.61, resulting in a loss of \$12,363,381.51.

Mr. Gonzales presented the Statement of Revenues and Expenditures for the period ending August 31, 2023, for the Program Support Fund. Mr. Gonzales reported revenue of \$147,257.00 and expenses of \$148,842.98, which resulted in a loss of \$1,585.98 for August. Year-to-date total revenues are \$273,930.00, and expenses were \$272,078.07, resulting in a gain of \$1,851.98 for the fiscal year.

Mr. Gonzales presented the Balance Sheet for the Agency for the period ending August 31, 2023. Program Support had total assets of \$956,893.04, total liabilities of \$260,377.51, and total fund equity of \$696,515.53. Employee Benefits had total assets of \$44,032,219.83, total liabilities of \$37,615,794.94, and total fund equity of \$6,416,424.89. Risk had total assets of \$174,651,029.48, total liabilities of \$175,659,264.06, and a total fund equity of negative \$1,008,234.58. The total combined fund equity for the agency was \$6,104,705.84.

A motion was made to approve the Financial Reports for August 2023 as presented.



**MOTION:** T. Ruiz

**SECONDED:** S. Quintana

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**8. B. Approval of Financial Reports - September 2023 (Action Item)**

Ms. Charlette Probst, Financial/HR Manager NMPSIA, presented the Statement of Revenues and Expenditures for the period ending September 30, 2023, for the Employee Benefits Fund. Ms. Probst reported revenue of \$28,097,031.03 and expenses of \$24,671,517.34, resulting in a gain for September of \$3,425,513.69. Year-to-date revenues were \$85,772,614.12, and expenses were \$93,512,341.93, resulting in a loss of \$7,739,727.81.

Ms. Probst presented the Statement of Revenues and Expenditures for the period ending September 30, 2023, for the Risk Fund. Ms. Probst reported revenue of \$8,054,798.41 and expenses of \$2,101,533.92, which resulted in a gain of \$5,953,264.49 for September. Year-to-date revenue was \$25,398,459.51, and expenses were \$31,808,576.53, resulting in a loss of \$6,410,117.02.

Ms. Probst presented the Statement of Revenues and Expenditures for the period ending September 30, 2023, for the Program Support Fund. Ms. Probst reported revenue of \$136,957.00 and expenses of \$129,659.66, which resulted in a gain of \$7,297.34 for September. Year to date total revenues were \$410,887.00 and expenses were \$401,737.73, resulting in a gain of \$9,149.27 for the fiscal year.

Ms. Probst presented the Balance Sheet for the Agency for the period ending September 30, 2023. Program Support had total assets of \$968,873.13, total liabilities of \$265,060.26, and total fund equity of \$703,812.87. Employee Benefits had total assets of \$42,254,169.89, total liabilities of \$32,412,231.31, and total fund equity of \$9,841,938.58. Risk had total assets of \$172,165,456.70, total liabilities of \$167,220,426.79, and total fund equity of \$4,945,029.91. The total combined fund equity for the agency was \$15,490,781.36.

A motion was made to approve the Financial Reports for September 2023 as presented.

**MOTION:** K. Manis

**SECONDED:** T. Ruiz

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**8. C. FY23 Audit Update**

Mr. Gonzales reported that the Fiscal Year 2023 audit was submitted by the statutory deadline of November 1, 2023 to the Office of The State Auditor. The results are still not public information until we receive the release from Office of The State Auditor but in preliminary meetings NMPSIA has no audit findings.

**8. D. Retroactive Approval to Withdraw From Employee Benefits Long-Term Investment Portfolio (Action Item)**

Mr. Gonzales reported that due to large claims and the timing of when member premiums are received, NMPSIA has had to manage cash flow very stringently. In order to increase cash on hand and support ongoing cashflow needs, the Finance Team recommended withdrawing \$3,000,000 from the long-term investment fund managed by the New Mexico State Investment Council. Staff met with PFM Asset Management on October 1, 2023, to discuss our cashflow needs and get their recommendation on how to raise the funds. Funds may only be withdrawn from the SIC at the beginning of each month with communications due to the SIC a minimum of five (5) business days before month end. As a result of this restriction, and after consultation with PFM, NMPSIA staff proceeded with a withdrawal from the investment fund managed by the SIC. A letter requesting the \$3,000,000 withdrawal was sent to the SIC.

A motion was made to approve the Retroactive Approval to Withdraw From the Employee Benefits Long-Term Investment Portfolio.

**MOTION:** D. Martinez Jr.

**SECONDED:** P. Jaramillo

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**8. E. Rebalance of Risk Fund Long-Term Investment Portfolio (Action Item)**

Mr. Gonzales reported that PFM Asset Management is also recommending a rebalance within the International allocation in the Risk Fund. Sell/withdraw \$150,000 Non-US Developed Index Fund, Buy/contribute \$150,000 Non-US Emerging Market Index Fund. If approved, staff will submit this request by the 25th of November to be effective December 1st, 2023. ☐

A motion was made to approve the Rebalance of Risk Fund Long-Term Investment Portfolio.

**MOTION:** S. Quintana

**SECONDED:** K. Manis

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**8. F. Review of NMPSIA Long-Term Funds Investment Policy Statement**

Mr. Sandoval advised that it was time for a periodic review of the NMPSIA long-term investment policy. Mr. Sandoval advised that it was customary that the Board appoint the IFR Committee to review and make recommendations to the policy. Mr. Parrino offered the board members the opportunity to join the Committee.

**9. Risk Matters**

**9. A. TPA Reports**

**1. Property & Liability Monthly Claims Report**

Mr. Steve Vanetsky, CCMSI, reported on the Property & Liability Monthly Claims Report for September 2023. Property had 117 open claims, 17 new claims, and 5 claims were closed. Reserves were \$68,310,477.42, and payments were \$24,754,953.42 for a total of \$93,065,430.84. Liability had 394 open claims, 35 new claims, and 33 claims were closed. Reserves were at \$23,404,671.69, and payments were at \$10,542,100.39 for a total of \$33,946,772.08.

**2. Property & Liability Large Losses**

Mr. Vanetsky reported large losses for September 2023. At Artesia Public Schools, clothing caught fire in a dryer in the utility and training room inside the gym complex, triggering the sprinkler system. The majority of the damage was water and smoke. This claim is not close to the access layer but was reported to the excess carrier. Belen Consolidated Schools, one of the elementary schools, is reporting hail damage to the roof and the HVAC units. We are waiting to get the building consultant and the roofing engineer to help determine the cause of loss and date of loss this has also been reported to the excess carrier. Grants Cibola County Schools, kids playing in the gym kicked a ball that struck the head of the fire suppression line, causing it to rupture on the gym floor for fifteen to twenty minutes. This has been reported to the excess carrier. One liability, the first notice of a lawsuit, has been reported to NMPSIA, General Counsel, Poms and Associates, and the excess carrier.

**3. Workers' Compensation Monthly Claims Report**

Mr. Jerry Mayo, CCMSI, provided the Workers' Compensation Monthly Claims Report for Districts as of September 30, 2023. There were 977 open claims, 291 new claims, 35 reopened, and 223 claims were closed. Reserves were at \$14,121,637.30, and payments were \$48,696,369.34 for a total of \$62,818,006.64.

**4. Workers' Compensation Large Losses**

Mr. Mayo reported there were no large losses for September.

9. **B. CCMSI Staffing Update**

Mr. Rich Cangiolosi, CCMSI, provided the staffing update. Mr. Cangiolosi apologized for not being present for Mr. Kevin Sovereign's send-off but reported that Mr. Sovereign will stay on as a consultant for the foreseeable future to help with heavy-litigated claims. Also, he and Mr. Sovereign are working on a job description to try to find somebody to step in and start training and take over that role.

9. **C. Loss Prevention Update**

Mr. Larry Vigil, Poms and Associates, presented the Loss Prevention Abatement Report for September 2023. In September, there was a 77.63% abatement for non-capital recommendations. There were 238 total recommendations, total capital recommendations were 10, and total non-capital were 228. Corrected non-capital was 177, and corrected capital was 7, for a total of 184 corrected. The corrected recommendations percentage for September was 77.31%. Mr. Vigil updated on the critical hazard letter sent to Mesa View Elementary in Tucumcari. The preschool program using part of the facility will vacate as soon as they find an alternate space. Ms. Julie Garcia, Poms and Associates, presented upcoming conferences.

10. **Benefits Matters**

10. **A. Approval Domestic Partner Resolution- Dulce Independent Schools (Action Item)**

Ms. Kaylei Jones, Benefits/Wellness Coordinator NMPSIA, presented the Domestic Partner Resolution for Dulce Independent Schools. Dulce's governing board has adopted a resolution to offer health benefit coverage to domestic partners and domestic partners' children. Dulce Independent Schools will be contributing to the premium for any tier change that is created by adding the partner and the partner's children. NMPSIA staff is recommending approval of this petition. If approved, staff will work with the school to establish an effective date and enrollment period for Dulce employees.

A motion was made to approve the Domestic Partner Resolution- Dulce Independent Schools.

**MOTION:** T. Crone

**SECONDED:** K. Manis

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes

Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**10. B. Retroactive Approval of Connected EOI Amendment to The Standard Agreement (Action Item)**

Ms. Martha Quintana, NMPSIA Deputy Director, presented the amendment to The Standard agreement. Last month, the Board granted NMPSIA approval to finalize the language in the amendment. Once the amendment was executed, NMPSIA staff began working with Erisa and The Standard to implement the Connected EOI service. Staff is recommending the retroactive

A motion was made to approve the Connected EOI Amendment to The Standard Agreement.

**MOTION:** S. Quintana

**SECONDED:** D. Martinez Jr.

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**10. C. Approval of Amendment to Erisa Administrative Services, Inc. Agreement (Action Item)**

Ms. Quintana presented an amendment to the Erisa agreement. This is the third amendment added to the Scope of Work to include eLearning passive and interactive training for annual, monthly, and roundtable topic formats. It also updates existing eLearning trainings and makes them available on the website. The passive training consists of an automated PowerPoint presentation no longer than thirty minutes in length, whereas the interactive learning will be no longer than sixty minutes in length. Fees to deliver a new passive eLearning module shall not exceed \$2,000 per training, and fees to update an existing module shall not exceed \$1,000. Fees for new and the updating of existing interactive training shall not exceed \$5,000 and \$2,500 respectively. Erisa has proposed offering an additional Annual Regional Training segment in June 2024. The cost for providing an additional Annual Regional Training shall not exceed \$40,000, excluding gross receipts tax. Staff is recommending approval of this amendment to the Erisa agreement.

A motion was made to approve the Amendment to Erisa Administrative Services, Inc. Agreement.

**MOTION:** D. Martinez Jr.

**SECONDED:** S. Quintana

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**10. D. Approval of Change to the Segal Amendment for Mental Health Parity Audit (Action Item)**

Dr. Nura Patani, Segal, presented the change to the Segal amendment for the Mental Health Parity Audit. This amendment was approved by the Board at the July 20, 2023 meeting however it was not executed due to newly issued Federal guidance. Not being able to opt-out, NMPSIA is required to follow the new guidelines and is subject to potential audits. The proposed amendment scales back on the preliminary review of Non-Quantitative Treatment Limits until the final regulations are released and proceeds with the complete review of Quantitative Treatment Limits. Upon finalization of the regulations, Segal will provide a supplemental proposal for any additional work required by the new guidance.

A motion was made to approve the Amendment of Mental Health Parity Audit.

**MOTION:** K. Manis

**SECONDED:** T. Crone

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

#### 10. E. Stop Loss Carrier Update

Dr. Patani presented the Stop Loss Carrier Procurement Update. Segal solicited proposals on behalf of NMPSIA from stop-loss insurers to cover medical and prescription drug claimants over \$1,000,000 for an effective date of January 1, 2024. Segal requested pricing proposals to include a \$500,000 aggregate-specific deductible. Proposals were submitted by Matrix Group Benefits, Sun Life Financial, and Symetra Life Insurance Company. Symetra did not submit a complete proposal prior to the deadline. Matrix proposed a 12.3% increase from the current premium rate. Sun Life and Symetra proposed a 59.8% and 92.7% increase, respectively. Dr. Patani shared that the next steps include Segal releasing the updated large claimant experience to obtain firm Best and Final Offers. The analysis will be presented at the December BAC and Board meetings for approval and award. Mr. Parrino asked how often the coverage is utilized. Dr. Patani did not have the utilization at this time. Mr. Parrino requested a summary by year of stop loss claims.

#### 10. F. Respiratory Syncytial Virus (RSV) Update

Dr. Patani shared the RSV Update. Regarding Flu, FY19-20 saw spikes during November 2019 and February 2020. Dr. Patani reported a subdued experience in FY20-22 adding that exposure was reduced through social distancing and masking. The FY22-23 experience was higher and occurred earlier than the compared years. Patterns are consistent across employees and dependents as well as the various carriers and plan options. Regarding RSV, the FY22-23 experience is significantly higher than historically tracked. RSV is primarily among employees and children; RSV counts for spouses have been consistently minimal.



## 10. G. Annual Carrier Updates

### 1. CVS

Mr. David Lauck and Ms. Lara Clower presented the CVS Carrier Update. Ms. Clower shared CVS has launched Cordavis, a subsidiary that will work with manufacturers to bring biosimilar products to the U.S pharmaceutical market. Cordavis is contracted with Sandoz to commercialize Hyrimoz, a biosimilar for Humira in the beginning of 2024. This will result in a more than 80% reduction in the current list price of Humira. For the period, NMPSIA's drug mix showed an 83.2% generic dispensing rate and 15.5% single-source brand utilization which is driven by GLP-1 and Covid costs. Of the total number of prescriptions, 18.7% are being filled under Retail 90 which is significantly higher than peer utilization. Mr. Lauck reported that Rheumatoid Arthritis, Oncology, Psoriasis, HIV and Crohn's Disease are the top five specialty drugs by gross cost.

### 2. BCBS

Ms. Marlene Baca presented the BCBS Carrier Update. NMPSIA's BCBS enrollment dropped by 1% for the period. Total claim spend came in at \$150.5 million, and paid PMPM increased from \$511 million to \$523 million. NMPSIA realized almost \$200 million in discount savings as the majority of members are seeing a PPO provider. Neoplasms and Musculoskeletal were two of the top ten most costly diagnostic categories. Telehealth visit utilization is split almost evenly between behavioral health and medical. There were a total of 202 High Cost Claimants (HCCs). There were 68 neoplasm HCCs and 22 musculoskeletal HCCs contributing to the total count. In the prior period, neoplasm and musculoskeletal HCCs were 54 and 19, respectively. Ms. Baca reported on ER utilization. Of the "frequent flyers," members with ten or more visits to the ER for the period all were determined to be appropriate visits.

Ms. Baca shared that participation in the wellness program has increased significantly. In the prior period there were 54 participants in health education webinars. That number was reported to be 294 participant in the current period. Walker tracker participation also increased from 321 to 454 for the reporting period. New initiatives include a benefits newsletter and a carrier event calendar. Upcoming opportunities include the Blue Pulse survey, FitKits and a new wellness resource- one stop shop flier. The Blue Access for Members platform (BAM) saw a decreased utilization of 9.09%.

### 3. Cigna

Mr. Daniel Warner provided the Cigna Carrier Update. Membership increased 73% from the prior period and employee preventative care rates increased 1.6% though they are still below the norm. ER visits increased 45% from the prior period with 13 out of 16 steerable visits having an urgent care facility within 10 miles. Virtual care visits came in at 26%. Related to chronic conditions, 35% of the population received an outreach for chronic condition coaching. Plan spending totaled \$2.4 million and the top 3 diagnostic groups accounted for 47% of medical spend. These include musculoskeletal, neurological, and pregnancy. Mr. Warner shared health engagement stats. NMPSIA's population has a 30% well-visit rate and a 73% breast cancer screening rate which are both above benchmark. 26% of the population used virtual care. The top five chronic conditions include depression, weight, low back pain, diabetes, osteoarthritis, and hypertension.

NMPSIA realized a savings of \$209,000 by utilizing medical management and chronic condition coaching. 40% of members with depression have other chronic conditions and comorbidities. 23% of members with behavioral health conditions make up 43% of the total plan spend. Behavioral health virtual visits are up 24% in the current period. Only one performance guarantee metric was missed, and NMPSIA has since received the appropriate payout.

#### **10. H. Clinic Feasibility Study Update**

Ms. Jones provided the Clinic Feasibility Study update. NMPSIA received feedback from General Council and the Benefits Consultant on the RFI for the Viability of Plan-Owned Medical Clinics. The feedback mostly consisted of the addition of clarifying language. NMPSIA has contacted the IBAC chair, APS, to get on the next IBAC meeting agenda scheduled for November 8, 2023. At this meeting, NMPSIA will present the RFI to the other IBAC partners to gauge their interest in participating as well as collect any feedback our partners may have. After gauging their interest, NMPSIA will work on collecting the data from the other agencies and releasing the RFI with a target date of December 1st.

#### **10. I. IBAC Update**

Ms. Cyndi Archuleta, Benefits/Wellness Operations Manager for NMPSIA, presented the IBAC Update. The IBAC meeting was held on Wednesday, October 11, 2023, where the IBAC agencies heard presentations on Glucagon-like peptide 1 (GLP-1) drugs from CVS and ESI. GLP-1 agonists are a second class of drugs that increase insulin release, delay digestion, and decrease appetite, which help to reduce body weight by 15% on average. During the discussion CVS and ESI provided information on what GLP-1 agents are, the cost impact to employers, trends, as well as the various unknown components related to utilization, side-effects, and long-range implications. United Concordia Dental and Cigna both reported that they made monetary donations to two local programs. United Concordia recently installed a new digital sign at the I-25/I-40 junction. Delta Dental announced the departure of a dentist from the Farmington area, they assured us that there are still 44 other dentists in the area but agreed to provide an impact report.

#### **11. General Discussion**

Mr. Parrino thanked the vendors and NMPSIA staff for all they do for the members.

**12. Next Meeting Date and Location (Action Item)**

Next Meeting Date: Thursday, December 7, 2023

Location: Poms & Associates 201 3rd Street, Suite 1400 and a virtual option

A motion was made to approve Next Meeting Date and Location.

**MOTION:** S. Quintana

**SECONDED:** T. Ruiz

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes
Sammy Quintana	Yes

**Vote carried unanimously.**

**13. Adjournment (Action Item)**

A motion was made to adjourn the meeting at 10:45 am.

**MOTION:** T. Crone

**SECONDED:** K. Manis

A roll call vote was taken.

Ms. Charlette Probst called roll.

Al Park, President	Absent
Chris Parrino, Vice-President	Yes
Trish Ruiz, Secretary	Yes
Denise Balderas	Absent
Vicki Chavez	Yes
Tim Crone	Yes
Pauline Jaramillo	Yes
Bethany Jarrell	Yes
K.T. Manis	Yes
David Martinez Jr.	Yes

# Public Schools Insurance Authority



**Board Meeting**

**Fiscal Year 2024**

**October 2023 Financial Reports**

**December 7, 2023**

**NM Public Schools Insurance Authority**  
**Statement of Revenues and Expenditures - Employee Benefits Fund**  
**From 10/1/2023 Through 10/31/2023**

	Prior Year Current Period Actual	Current Period Actual	Current Period % Change	Prior Year Actual	Current Year Actual	Current Year % Change
<b>Revenue</b>						
Premiums (Health Insurance Assessments)	28,849,210.82	31,397,055.79	8.83	109,932,979.69	117,743,519.69	7.10
Interest Income (Wells Fargo, LGIP)	31,566.79	26,194.77	(17.02)	145,077.38	173,151.44	19.35
Investment Income (SIC)	944,452.58	(637,330.67)	(167.48)	(319,034.73)	(1,359,090.51)	326.00
Miscellaneous Income (Rx Rebates, Penalties, Subros, Etc)	0.00	1,152.02	100.00	0.00	2,105.41	100.00
<b>Total Revenue</b>	<b>29,825,230.19</b>	<b>30,787,071.91</b>	<b>3.22</b>	<b>109,759,022.34</b>	<b>116,559,686.03</b>	<b>6.20</b>
<b>Expenditures</b>						
Medical Claims Expense	17,010,872.35	27,867,470.47	63.82	78,396,206.93	94,966,576.42	21.14
Prescription Claims Expense	3,310,307.82	4,913,024.88	48.42	13,015,342.53	19,388,919.78	48.97
Dental Claims Expense	983,717.27	1,016,640.28	3.35	4,513,470.00	4,644,871.15	2.91
Premiums (Life, Vision)	1,129,170.50	1,311,077.05	16.11	4,454,721.70	5,194,705.78	16.61
Claims Administration Fees (Medical, Dental, Rx)	1,157,845.40	1,228,970.45	6.14	4,624,480.21	4,731,651.33	2.32
Contractual Services (Erisa, Segal, Legal, Etc)	228,848.55	232,769.67	1.71	1,039,704.95	949,681.27	(8.66)
Transfer to Program Support	63,333.00	68,479.00	8.13	253,336.00	274,368.00	8.30
<b>Total Expenditures</b>	<b>23,884,094.89</b>	<b>36,638,431.80</b>	<b>53.40</b>	<b>106,297,262.32</b>	<b>130,150,773.73</b>	<b>22.44</b>
<b>Net Revenue &amp; Expenditures</b>	<b>5,941,135.30</b>	<b>(5,851,359.89)</b>	<b>(198.49)</b>	<b>3,461,760.02</b>	<b>(13,591,087.70)</b>	<b>(492.61)</b>

**NM Public Schools Insurance Authority**  
**Statement of Revenues and Expenditures - Risk Fund**  
**From 10/1/2023 Through 10/31/2023**

	Prior Year Current Period Actual	Current Period Actual	Current Period % Change	Prior Year Actual	Current Year Actual	Current Year % Change
<b>Revenue</b>						
Premiums (Risk Insurance Assessments)	7,737,270.00	8,354,878.00	7.98	30,949,124.00	33,419,546.80	7.98
Interest Income (Wells Fargo, LGIP)	185,648.96	425,294.12	129.09	500,825.31	1,317,924.79	163.15
Investment Income (SIC)	738,783.56	(494,592.51)	(166.95)	(240,108.58)	(1,054,521.00)	339.19
Miscellaneous Income (Penalties, Subros, Etc)	0.00	0.00	0.00	1.04	1,088.53	....566.35
<b>Total Revenue</b>	<b>8,661,702.52</b>	<b>8,285,579.61</b>	<b>(4.34)</b>	<b>31,209,841.77</b>	<b>33,684,039.12</b>	<b>7.93</b>
<b>Expenditures</b>						
<b>Property - Liability Claims Expense</b>						
Property Claims	545,305.82	226,238.32	(58.51)	3,885,070.91	3,952,269.89	1.73
Liability Claims	1,256,292.29	1,756,445.88	39.81	10,151,504.07	5,566,488.31	(45.17)
P-L Provisions for Losses	217,078.11	2,489,258.26	1,046.71	2,117,440.70	6,084,200.70	187.34
P-L Excess Recoveries	(70,159.36)	798,760.40	(1,238.49)	(8,184,626.76)	(947,021.99)	(88.43)
P-L Excess Recoveries Distributed to Schools	18,667.51	0.00	(100.00)	3,857,287.70	0.00	(100.00)
<b>Total Property - Liability Claims Expense</b>	<b>1,967,184.37</b>	<b>5,270,702.86</b>	<b>167.93</b>	<b>11,826,676.62</b>	<b>14,655,936.91</b>	<b>23.92</b>
Workers' Compensation Claims Expense	640,047.37	2,374,525.96	270.99	3,700,198.37	4,774,550.19	29.03
Property Excess Coverage Premium	2,586,540.00	3,597,631.00	39.09	10,346,168.00	14,390,524.21	39.09
Liability Excess Coverage Premium	1,771,250.00	2,099,839.00	18.55	7,085,000.00	8,399,361.00	18.55
Workers' Compensation Excess Coverage Premium	39,900.00	43,977.00	10.22	159,609.00	176,753.00	10.74
Student Catastrophic Insurance Premium	18,240.00	18,269.00	0.16	72,968.62	73,080.18	0.15
Equipment Breakdown Insurance Premium	34,196.00	38,266.00	11.90	136,788.62	153,067.62	11.90
Property - Liability Claims Administration Fees	94,196.10	94,184.86	(0.01)	376,892.62	376,739.56	(0.04)
Workers' Compensation Claims Administration Fees	104,051.99	98,749.05	(5.10)	416,327.61	399,296.68	(4.09)
Contractual Services (Erisa, Poms, CCMSI, Legal, Etc)	259,974.74	292,814.23	12.63	2,053,436.33	2,133,228.14	3.89
Transfer to Program Support	63,340.00	68,478.00	8.11	253,380.00	273,476.00	7.93
<b>Total Expenditures</b>	<b>7,578,920.57</b>	<b>13,997,436.96</b>	<b>84.69</b>	<b>36,427,445.79</b>	<b>45,806,013.49</b>	<b>25.75</b>
<b>Net Revenue &amp; Expenditures</b>	<b>1,082,781.95</b>	<b>(5,711,857.35)</b>	<b>(627.52)</b>	<b>(5,217,604.02)</b>	<b>(12,121,974.37)</b>	<b>132.33</b>

**NM Public Schools Insurance Authority**  
**Statement of Revenues and Expenditures - Program Support Fund**  
**From 10/1/2023 Through 10/31/2023**

	Prior Year Current Period Actual	Current Period Actual	Current Period % Change	Prior Year Actual	Current Year Actual	Current Year % Change
<b>Revenue</b>						
Transfers from Other Funds (Benefits, Risk)	126,673.00	136,957.00	8.12	506,716.00	547,844.00	8.12
Miscellaneous Income	0.00	0.12	100.00	26.50	0.12	(99.55)
<b>Total Revenue</b>	<b>126,673.00</b>	<b>136,957.12</b>	<b>8.12</b>	<b>506,742.50</b>	<b>547,844.12</b>	<b>8.11</b>
<b>Expenditures</b>						
Contractual Services (Professional, Audit, Legal, Etc)	38,684.49	33,782.91	(12.67)	44,133.73	39,977.12	(9.42)
Other Expenses (Travel, Maint., Supplies, Utilities, Etc.)	19,366.30	13,887.24	(28.29)	47,389.23	63,464.93	33.92
Per Svc/Ben (Salaries, Fringe Benefits)	72,956.34	120,401.31	65.03	300,822.60	466,367.14	55.03
<b>Total Expenditures</b>	<b>131,007.13</b>	<b>168,071.46</b>	<b>28.29</b>	<b>392,345.56</b>	<b>569,809.19</b>	<b>45.23</b>
<b>Net Revenue &amp; Expenditures</b>	<b>(4,334.13)</b>	<b>(31,114.34)</b>	<b>617.89</b>	<b>114,396.94</b>	<b>(21,965.07)</b>	<b>(119.20)</b>

**NM Public Schools Insurance Authority**

**Balance Sheet**

**As of 10/31/2023**

	<u>Program Support</u>	<u>Employee Benefits</u>	<u>Risk</u>	<u>Total</u>
<b>ASSETS</b>				
Cash (Wells Fargo/State Treasurer)	703,962.57	312,654.48	855,225.77	1,871,842.82
Short-term Investments (LGIP)	0.00	1,835,654.21	92,612,093.62	94,447,747.83
Long-term Investments (SIC)	0.00	23,598,378.34	18,303,437.19	41,901,815.53
Receivables (LGIP Int., W/C Excess Carrier)	(0.80)	24,856.90	3,729,723.49	3,754,579.59
Prepaid Premiums (Risk Excess Coverage)	0.00	0.00	46,383,856.00	46,383,856.00
Other Assets (Deposits, Furniture, Fxtures, Equip., Etc)	245,361.25	11,438,072.14	319,145.15	12,002,578.54
<b>Total ASSETS</b>	<b>949,323.02</b>	<b>37,209,616.07</b>	<b>162,203,481.22</b>	<b>200,362,420.31</b>
<b>LIABILITIES</b>				
Accounts Payable (Admin Fees)	2,339.82	1,414,205.12	485,748.15	1,902,293.09
Case Reserves (P/L, W/C)	0.00	0.00	46,708,230.81	46,708,230.81
IBNR (Incurred But Not Reported)	0.00	23,405,795.00	48,236,047.00	71,641,842.00
Claims Payable (Medical, Dental, P/L, W/C)	0.00	8,335,220.18	701,258.70	9,036,478.88
Deferred Revenue (Self-Pays, P/L, W/C Premiums)	0.00	63,816.48	66,839,024.00	66,902,840.48
Other (Payroll Taxes, Benefits, Compensated Absences Payable)	274,284.67	0.60	0.00	274,285.27
<b>Total LIABILITIES</b>	<b>276,624.49</b>	<b>33,219,037.38</b>	<b>162,970,308.66</b>	<b>196,465,970.53</b>
<b>FUND EQUITY</b>				
Beginning Fund Equity	694,663.60	17,581,666.39	11,355,146.93	29,631,476.92
Net Revenue & Expenditures (Year-to-Date)	(21,965.07)	(13,591,087.70)	(12,121,974.37)	(25,735,027.14)
<b>Total FUND EQUITY</b>	<b>672,698.53</b>	<b>3,990,578.69</b>	<b>(766,827.44)</b>	<b>3,896,449.78</b>





# New Mexico Public Schools Insurance Authority

## Investment Performance Review For the Quarter Ended September 30, 2023

Client Management Team

PFM Asset Management LLC

---

Ellen Clark, Director  
Mallory Sampson, CFP, Director  
Chrystal Thomas, Analyst

1820 East Ray Road  
Chandler, AZ 85225  
855-885-9621

1735 Market Street  
43rd Floor  
Philadelphia, PA 19103

---

# **Markets and Economy**

	QTD	YTD	1 Year	3 Years	5 Years	7 Years	10 Years
<b>DOMESTIC EQUITY</b>							
S&P 500	-3.27%	13.07%	21.62%	10.15%	9.92%	12.24%	11.91%
Russell 3000 Index	-3.25%	12.39%	20.46%	9.38%	9.14%	11.64%	11.28%
Russell 1000 Value Index	-3.16%	1.79%	14.44%	11.05%	6.23%	7.92%	8.45%
Russell 1000 Growth Index	-3.13%	24.98%	27.72%	7.97%	12.42%	15.64%	14.48%
Russell Midcap Index	-4.68%	3.91%	13.45%	8.09%	6.38%	8.68%	8.98%
Russell 2500 Index	-4.78%	3.59%	11.28%	8.39%	4.55%	7.96%	7.90%
Russell 2000 Index	-5.13%	2.54%	8.93%	7.16%	2.40%	6.62%	6.65%
Russell 2000 Value Index	-2.96%	-0.53%	7.84%	13.32%	2.59%	5.94%	6.19%
Russell 2000 Growth Index	-7.32%	5.24%	9.59%	1.09%	1.55%	6.77%	6.72%
<b>INTERNATIONAL EQUITY</b>							
MSCI EAFE (Net)	-4.11%	7.08%	25.65%	5.75%	3.24%	5.29%	3.82%
MSCI AC World Index (Net)	-3.40%	10.06%	20.80%	6.89%	6.46%	8.60%	7.56%
MSCI AC World ex USA (Net)	-3.77%	5.34%	20.39%	3.74%	2.58%	4.73%	3.35%
MSCI AC World ex USA Small Cap (Net)	-1.70%	5.03%	19.01%	4.01%	2.58%	4.70%	4.35%
MSCI EM (Net)	-2.93%	1.82%	11.70%	-1.73%	0.55%	3.22%	2.07%
<b>ALTERNATIVES</b>							
FTSE NAREIT Equity REIT Index	-7.13%	-2.14%	2.99%	5.76%	2.77%	2.61%	5.96%
FTSE EPRA/NAREIT Developed Index	-5.59%	-4.10%	2.72%	1.54%	-0.29%	0.65%	2.97%
Bloomberg Commodity Index Total Return	4.71%	-3.44%	-1.30%	16.23%	6.13%	4.68%	-0.75%
<b>FIXED INCOME</b>							
Blmbg. U.S. Aggregate	-3.23%	-1.21%	0.64%	-5.21%	0.10%	-0.09%	1.13%
Blmbg. U.S. Government/Credit	-3.00%	-0.86%	0.93%	-5.32%	0.41%	0.09%	1.31%
Blmbg. Intermed. U.S. Government/Credit	-0.83%	0.65%	2.20%	-2.93%	1.02%	0.62%	1.27%
Blmbg. U.S. Treasury: 1-3 Year	0.71%	1.69%	2.44%	-0.92%	1.03%	0.77%	0.79%
Blmbg. U.S. Corp: High Yield	0.46%	5.86%	10.28%	1.76%	2.96%	3.80%	4.24%
Credit Suisse Leveraged Loan index	3.37%	9.91%	12.47%	5.91%	4.31%	4.64%	4.33%
ICE BofAML Global High Yield Constrained (USD)	0.08%	5.37%	12.71%	-0.14%	1.81%	2.84%	3.29%
Blmbg. Global Aggregate Ex USD	-4.00%	-3.20%	3.39%	-8.39%	-3.10%	-2.77%	-1.73%
JPM EMBI Global Diversified	-2.23%	1.76%	10.01%	-4.56%	-0.35%	0.11%	2.47%
<b>CASH EQUIVALENT</b>							
90 Day U.S. Treasury Bill	1.31%	3.60%	4.47%	1.70%	1.72%	1.54%	1.10%

Source: Investment Metrics. Returns are expressed as percentages. Please refer to the last page of this document for important disclosures relating to this material.

**THE ECONOMY**

▶ In the second quarter, U.S. gross domestic product (GDP) grew at an annualized rate of 2.1%, in line with 2023 growth estimates by the Federal Reserve (Fed) despite persistent inflation and continued rate hikes. This GDP growth rate is below global GDP growth estimates of 3.0%, which have been buoyed by emerging markets (EM) and developing economies.


▶ The U.S. labor market continues to cool as the unemployment rate has risen to 3.8% in September. The number of job openings to unemployed ratio fell to 1.51, down from its high of 2.0 in 2022 but not yet closing in on the goal of 1.00.

▶ Inflation pressures remained visible in the third quarter, with headline inflation (CPI) increasing 3.7% year-over-year (YoY) in September, up from 3.0% at the end of the second quarter. However, the less volatile core reading (which excludes food and energy) shows continued cooling at 4.1% YoY in September, its slowest pace since 2021.


▶ Through the strong labor market and continued growth, consumer confidence saw relative improvement. The Michigan Consumer Sentiment survey ended the quarter at 68.1, up 8.4 year-to-date, though below the long-term average of 85. Consumers savings and incomes remain strong, but debt levels and defaults are increasing.



Source: IMF. Dark blue bars indicate actual numbers; light blue bars indicate forecasted estimates.




Source: Bureau of Labor Statistics.




Source: Bureau of Labor Statistics.

**WHAT WE'RE WATCHING**


- ▶ After a pause in June, the third quarter brought one more rate hike as the resiliency of economic activity in the U.S. prompted the Fed to raise the target for the federal funds rate by 25 basis points (bps). Looking forward, the median dot for 2024 and 2025 were raised to 5.125% and 3.875%, with increased expectations of a 'higher-for-longer' policy. The European Central Bank (ECB) diverged from Fed policy slightly with two hikes during the quarter, marking a full year of consecutive rate hikes, as they continue to rein in inflation.
- ▶ The U.S. saw some recovery in manufacturing during the quarter as S&P Global U.S. Manufacturing rose to 49.8, just fractionally contractionary, as supply conditions improved and employment rose. Services weakened over the quarter, but remain expansionary at 50.1. The HCOB Eurozone manufacturing PMI, by comparison, ended the quarter in sharply contractionary territory for the fifteenth consecutive month, at 43.4. The services PMI also turned contractionary ending at 48.7.
- ▶ China's manufacturing and services sectors saw continued growth but with slowing momentum through the quarter as the S&P Global China Manufacturing and Services readings dipped to 50.9 and 50.2, respectively. Looking forward, the expected increased domestic tourism for "golden week" may provide a short-term boost to demand, though whether that can be sustained remains to be seen.



Source: Bloomberg.



Source: Bloomberg.




Source: Bloomberg.

**DOMESTIC EQUITY**

- ▶ The S&P 500 Index (S&P) posted a return of -3.27% for the third quarter of 2023. As of September 30, 2023, the trailing 1-year return for the index was 21.59%.
- ▶ Over the quarter, extreme market concentration continued to play a factor for large-cap stocks, as evidenced by the underperformance of the S&P 500 Equal Weight Index versus the S&P 500 Market Cap-Weighted Index.
- ▶ Within the S&P, only two of the 11 Global Industry Classification Standard (GICS) sectors posted positive gains for the quarter: Energy (12.22%) and Communication Services (3.07%). The worst-performing sectors over the quarter were Utilities (-9.25%), Real Estate (-8.90%), and Consumer Staples (-5.97%).
- ▶ Small-caps, as represented by the Russell 2000 Index, returned -5.13% during the quarter, lagging mid- and large-caps. The Russell Mid Cap Index returned -4.68% for the quarter, while the Russell 1000 Index returned -3.16%.
- ▶ According to FactSet Earnings Insight (as of September 29, 2023), the expected YoY earnings growth rate for the S&P for the third quarter is -0.1%. If expectations become a reality, it will be the fourth consecutive quarterly decline for the index.
- ▶ As of the end of the quarter, the S&P 500 P/E ratio was 20.96, below its 5-year average of 21.74. By comparison, the S&P 600, which represents small-cap stocks, had a P/E ratio of 14.52, well below its 5-year average of 17.22.


**S&P 500 Index Performance by Sector**

Periods Ended September 30, 2023



Source: Bloomberg.

**P/E Ratios of Major Stock Indices\***



Source: Bloomberg.


\*P/E ratios are calculated based on one-year forward estimates and adjusted to include only positive earnings results for consistency.

**NON-U.S. EQUITY**

- ▶ Markets outside of the U.S., as measured by the MSCI ACWI ex-U.S. Index, slightly underperformed their U.S. counterparts, returning -3.77% for the quarter.
- ▶ There were 10 out of the 11 sectors that posted negative returns for the quarter, with Information Technology (-8.71%), Utilities (-7.89%), and Consumer Staples (-6.38%) being the worst-performing sectors. Energy (+8.96%) was the best and only sector with a positive return for the quarter. The sector benefited from oil prices soaring on tighter supplies.
- ▶ Emerging markets (EM), as represented by MSCI Emerging Market Index, outperformed Developed ex-U.S. Markets, represented by the MSCI EAFE Index, returning -2.93% versus -4.11% for the quarter.
- ▶ MSCI Japan (-1.55%) outperformed the MSCI EAFE Index. Japanese equities continue to benefit from positive investor sentiment as better corporate governance practices and attractive valuation brighten earnings outlook. Of the five largest-weighted countries in the index, Germany (-7.62%) was the worst performer due to gloomy economic data and unfavorable demographics.
- ▶ Within EM, MSCI India (1.84%) was a strong performer. The country's economic growth remains strong despite higher rates. MSCI China (-2.41%) outperformed the index as the government reaffirmed stimulative policies, which fueled a sharp rebound in Chinese equities during the month of July.
- ▶ Small-caps, as represented by MSCI ACWI ex-U.S. Small Cap Index, outperformed within the international equity markets, returning -1.70% for the quarter.
- ▶ Non-U.S. equities remain undervalued relative to their long-term average across international equity markets. As of September 30, 2023, MSCI EAFE ended the quarter with a P/E ratio of 13.39, much lower than its 5-year average of 15.98. Similarly, MSCI EM's P/E stood at 12.99 versus a 5-year average of 13.12.


**MSCI ACWI ex-U.S. Sectors**

Periods Ended September 30, 2023



Source: Bloomberg.

**P/E Ratios of MSCI Equity Indices\***




Source: Bloomberg.

\*P/E ratios are calculated based on one-year forward estimates and adjusted to include only positive earnings results for consistency.

**FIXED INCOME**

- ▶ The U.S. bond market represented by the Bloomberg U.S. Aggregate (Aggregate) Index fell sharply during the third quarter to -3.23% as rates continued rising. The trailing 1-year period return is 0.64%.
- ▶ The Bloomberg U.S. Treasury Index closed the quarter with a loss of -3.06%. During the period, the Federal Open Market Committee (FOMC) raised interest rates by a quarter point in July, but paused at the September meeting. Long rates rose on several factors, including higher overall treasury issuance, less foreign demand, stickier energy-related inflation, and Federal debt and deficit size. The latter led to Fitch downgrading the U.S. Government rating. The curve remains inverted as the fed funds rate is now targeted at 5.5%. The 10-year climbed 78 bps in the quarter, ending at 4.59%.
- ▶ Corporate credit had mixed results for the quarter. The investment-grade Bloomberg U.S. Corporate (IG Corp) Index declined 3.09%, while high-yield bonds, as represented by the Bloomberg U.S. Corporate High-Yield (HY) Index, posted a gain of 0.46%. Although spreads didn't widen, IG Corp sold off from duration. HY saw very mild spread widening but was again led by the lowest quality Caa/CCC-rated cushioned by double-digit yields.
- ▶ The fixed-rate mortgage market, as measured by the Bloomberg U.S. Mortgage-Backed Securities (MBS) Index, lost 4.05%, hurt by continued duration extension on higher rates. On the commercial side, the Bloomberg U.S. Agency CMBS Index declined by 1.91%.
- ▶ EM USD sovereign bonds, as represented by the JP Morgan EMBI Global Diversified Index, lost 2.23%.


U.S. Treasury Yield Curve



Source: Bloomberg.

Returns for Fixed-Income Segments

Periods Ended September 30, 2023



Source: Bloomberg.



**ALTERNATIVES**


▶ REITs, as measured by the FTSE NAREIT Equity REITs Index, fell 7.13% in the third quarter of 2023, compared to a 2.62% increase in the prior quarter. All major sectors posted losses during the quarter as higher interest rates and broader economic concerns have spooked investors. The best performers were the Office and Data Center sectors, which posted returns of -1.47% and -2.50%, respectively. The worst performers during the quarter were the Diversified and Self-Storage sectors, which posted returns of -13.92% and -12.19%, respectively.

▶ Commodity futures, represented by the Bloomberg Commodity Total Return Index, gained 4.71% in the third quarter of 2023, compared to a 2.56% decline in the prior quarter. The U.S. Dollar Index (DXY) gained 3.17% during the same period. The price of gold fell 3.69% in Q3, marking the second consecutive quarter of declines for the precious metal. Gold finished the quarter at \$1,848.63 per ounce, down from \$1,919.35 at the end of the previous quarter. The West Texas Intermediate (WTI) Crude Oil spot price gained 28.53% from \$70.64 to \$90.79 per barrel as news of OPEC cuts and tighter supplies outweighed headwinds posed by a strengthening U.S. dollar and softening economic data.

▶ Private real estate, as measured by the NCREIF Property Index, fell -1.98% in the second quarter of 2023, resulting in a -6.60% return over the twelve-month period ended June 2023. This was the third consecutive quarter of negative returns for the index, underscoring the weakness in private property values. Hotel properties were again the top performers, with a total return of 4.00% in the second quarter, comprised of 1.94% in income return and 2.06% in appreciation return. Office properties were again the worst performers with a total return of -5.79%, comprised of 1.21% in income return and -7.00% in appreciation return.

**FTSE NAREIT Sectors**


Periods Ended September 30, 2023



Source: Bloomberg.

**Returns for Liquid and Semi-Liquid Alternative Assets**

Periods Ended September 30, 2023



Sources: Bloomberg and Hedge Fund Research, Inc.

**ALTERNATIVES (continued)**


► In the second quarter of 2023, infrastructure funds raised only \$3.72 billion, although this is higher than the amount raised during the prior quarter. Almost all of this capital was raised by opportunistic infrastructure funds. Real assets dry powder has also fallen from previous years and stands at \$254.85 billion as of Q4 2022. Despite macroeconomic headwinds, the asset class continues to remain attractive due to its ability to provide moderate but consistent returns during periods of volatility, inflation and recession. According to PitchBook, infrastructure funds posted a return of 2.83% in Q1 2023. The asset class has generated an annualized return of 10.49% for the five years ended Q1 2023.

► In the second quarter of 2023, private debt fundraising amounted to \$56.38 billion, up from the prior quarter. Private debt dry powder has fallen to \$434.39 billion, although it remains above the long-term average. The asset class has performed well relative to public fixed income and may see more opportunities emerge in the near term as tightening lending standards push banks out of the private lending space. According to the Cliffwater Direct Lending Index, U.S. middle market loans, a proxy for private debt, posted a return of 2.81% in Q2 2023. The asset class has also generated an annualized return of 8.47% for the five years ended Q2 2023.

► In the second quarter of 2023, private capital fundraising was led by private equity funds, which closed on \$114.01 billion. Global private equity dry powder, which accounts for the bulk of private capital dry powder, remains high at \$1.32 trillion as of December 2022. Recent private equity performance has weakened as a result of high interest rates and a slowing economy; however, longer-term performance relative to public equities remains strong. According to Cambridge Associates, U.S. private equity posted a return of 2.69% in Q1 2023. The asset class has generated an annualized return of 18.47% for the five years ended Q1 2023.


► Hedge fund returns were positive quarter-to-date through August 2023, with the HFRI Fund Weighted Composite Index returning 1.05%. During the same period, the HFRI Macro (Total) Index returned 0.11%. The HFRI Equity Hedge (Total) Index and the HFRI Fund of Funds Index returned 0.85% and 0.95%, respectively.

**Returns for Private Capital Assets**



Source: NCREIF, PitchBook, Cliffwater, Cambridge Associates, manual inputs.  
As of March 31, 2023 - most recent period for which all performance data is available.

**Private Capital Fundraising & Dry Powder**



Sources: Pitchbook.

\* Total capital raised in 2023 as of June 30, 2023 - most recent period for which ALL fundraising data is available.

\*\* Cumulative dry powder as of most recent - December 31, 2022.

**Benefits Fund - Performance Review**

## Asset Allocation &amp; Performance


	Allocation		Performance(%)								
	Market Value (\$)	%	1 Quarter	Fiscal YTD	Year To Date	1 Year	3 Years	5 Years	7 Years	Since Inception	Inception Date
<b>Total Fund</b>	<b>24,235,709</b>	<b>100.00</b>	<b>-2.89</b>	<b>-2.89</b>	<b>6.13</b>	<b>14.09</b>	<b>2.92</b>	<b>4.19</b>	<b>5.46</b>	<b>5.07</b>	<b>07/01/2014</b>
<i>Blended Benchmark</i>			-3.33	-3.33	5.96	13.41	2.12	4.34	5.39	5.00	07/01/2014
<b>Domestic Equity</b>	<b>10,399,061</b>	<b>42.91</b>									
Large Cap Index	8,283,295	34.18	-3.14	-3.14	12.68	20.84	9.40	8.78	11.35	10.23	07/01/2014
<i>Russell 1000 Index</i>			-3.15	-3.15	13.01	21.19	9.53	9.63	12.00	10.61	07/01/2014
SMID Cap Alternative	2,115,766	8.73	-4.93	-4.93	1.17	N/A	N/A	N/A	N/A	-7.60	02/01/2023
<i>Russell 2500 Index</i>			-4.78	-4.78	3.59	11.28	8.39	4.55	7.96	-5.83	02/01/2023
<b>International Equity</b>	<b>5,533,394</b>	<b>22.83</b>									
Non US Developed- Active	4,162,410	17.17	-3.58	-3.58	6.33	N/A	N/A	N/A	N/A	-1.33	02/01/2023
<i>MSCI AC World ex USA (Net)</i>			-3.77	-3.77	5.34	20.39	3.74	2.58	4.73	-2.56	02/01/2023
Non US Emerging	1,370,985	5.66	-3.22	-3.22	1.97	12.25	-0.72	1.30	N/A	4.20	12/01/2016
<i>MSCI Emerging Markets Index</i>			-2.79	-2.79	2.16	12.17	-1.34	0.94	3.61	4.38	12/01/2016
<b>Fixed Income</b>	<b>8,303,254</b>	<b>34.26</b>									
Credit Plus Pool	8,303,254	34.26	-1.69	-1.69	1.97	4.35	-3.21	1.45	1.51	2.10	07/01/2014
<i>Blmbg. U.S. Aggregate</i>			-3.23	-3.23	-1.21	0.64	-5.21	0.10	-0.09	0.81	07/01/2014

Returns are net of fees.

Returns are expressed as percentages.

Plan Sponsor Peer Group Analysis

All Public Plans-Total Fund



	1 Quarter	Fiscal YTD	Year To Date	1 Year	3 Years	5 Years	7 Years
■ Total Fund	-2.89 (60)	-2.89 (60)	6.13 (13)	14.09 (7)	2.92 (86)	4.19 (85)	5.46 (86)
● Blended Benchmark	-3.33 (79)	-3.33 (79)	5.96 (16)	13.41 (12)	2.12 (91)	4.34 (81)	5.39 (87)
5th Percentile	-0.27	-0.27	7.16	14.23	8.56	7.35	8.30
1st Quartile	-1.83	-1.83	5.46	12.18	6.01	5.93	7.32
Median	-2.60	-2.60	4.73	10.67	4.83	5.30	6.66
3rd Quartile	-3.21	-3.21	3.80	9.21	3.56	4.61	5.91
95th Percentile	-3.82	-3.82	2.23	5.30	1.11	2.83	4.26
Population	486	486	465	458	435	419	398

Parentheses contain percentile rankings.  
 Calculation based on monthly periodicity.  
 Returns are net of fees and are expressed as percentages.

## Financial Reconciliation

QTR				
	Market Value As of 07/01/2023	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	24,957,469	-	(721,760)	24,235,709
Large Cap Index	8,551,896	-	(268,601)	8,283,295
SMID Cap Alternative	2,225,435	-	(109,669)	2,115,766
Non US Developed- Active	4,317,091	-	(154,681)	4,162,410
Non US Emerging	1,416,641	-	(45,656)	1,370,985
Credit Plus Pool	8,446,407	-	(143,153)	8,303,254

July 1, 2023 To September 30, 2023				
	Market Value As of 07/01/2023	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	24,957,469	-	(721,760)	24,235,709
Large Cap Index	8,551,896	-	(268,601)	8,283,295
SMID Cap Alternative	2,225,435	-	(109,669)	2,115,766
Non US Developed- Active	4,317,091	-	(154,681)	4,162,410
Non US Emerging	1,416,641	-	(45,656)	1,370,985
Credit Plus Pool	8,446,407	-	(143,153)	8,303,254


## Financial Reconciliation

YTD				
	Market Value As of 01/01/2023	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	22,836,828	(25,130)	1,424,011	24,235,709
Large Cap Index	7,765,918	(450,540)	967,916	8,283,295
SMID Cap Alternative	-	2,096,714	19,052	2,115,766
Non US Developed- Active	-	3,858,991	303,419	4,162,410
Non US Emerging	1,409,679	(70,865)	32,171	1,370,985
Credit Plus Pool	6,561,350	1,640,452	101,453	8,303,254

1 Year				
	Market Value As of 10/01/2022	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	21,242,517	(31,431)	3,024,623	24,235,709
Large Cap Index	7,241,281	(450,727)	1,492,741	8,283,295
SMID Cap Alternative	-	2,096,714	19,052	2,115,766
Non US Developed- Active	-	3,858,991	303,419	4,162,410
Non US Emerging	1,280,577	(71,260)	161,667	1,370,985
Credit Plus Pool	6,411,239	1,637,790	254,225	8,303,254

Asset Allocation Compliance - Total Fund

	Asset Allocation (%)	Target Allocation (%)	Minimum Allocation (%)	Maximum Allocation (%)	Differences (%)
<b>Total Fund</b>	<b>100.0</b>	<b>100.0</b>	<b>N/A</b>	<b>N/A</b>	<b>0.0</b>
Domestic Equity	42.9	42.0	27.0	57.0	0.9
International Equity	22.8	23.0	8.0	38.0	-0.2
Fixed Income	34.3	35.0	15.0	55.0	-0.7





## Historical Hybrid Composition - Blended Benchmark

Allocation Mandate	Weight (%)
<b>Jul-2014</b>	
Russell 1000 Growth Index	20.0
Russell 1000 Value Index	20.0
Russell 2500 Index	10.0
MSCI EAFE (net)	10.0
Blmbg. Intermed. U.S. Government/Credit	35.0
90 Day U.S. Treasury Bill	5.0
<b>Jul-2015</b>	
Russell 3000 Index	36.0
MSCI AC World ex USA (Net)	19.0
Blmbg. U.S. Aggregate	45.0
<b>Dec-2021</b>	
Russell 3000 Index	42.0
MSCI AC World ex USA (Net)	23.0
Blmbg. U.S. Aggregate	35.0

**Risk Fund - Performance Review**

## Asset Allocation &amp; Performance


	Allocation		Performance(%)							
	Market Value (\$)	%	1 Quarter	Fiscal YTD	Year To Date	1 Year	3 Years	5 Years	Since Inception	Inception Date
<b>Total Fund</b>	<b>18,798,030</b>	<b>100.00</b>	<b>-2.89</b>	<b>-2.89</b>	<b>6.11</b>	<b>14.09</b>	<b>3.08</b>	<b>4.27</b>	<b>5.14</b>	<b>07/01/2014</b>
<i>Blended Benchmark</i>			-3.33	-3.33	5.96	13.41	2.12	4.34	5.00	07/01/2014
<b>Domestic Equity</b>	<b>8,059,782</b>	<b>42.88</b>								
Large Cap Index	6,410,275	34.10	-3.14	-3.14	12.61	20.77	10.41	9.39	10.58	07/01/2014
<i>Russell 1000 Index</i>			-3.15	-3.15	13.01	21.19	9.53	9.63	10.61	07/01/2014
SMID Cap Alternative	1,649,507	8.77	-4.93	-4.93	1.18	N/A	N/A	N/A	-7.59	02/01/2023
<i>Russell 2500 Index</i>			-4.78	-4.78	3.59	11.28	8.39	4.55	-5.83	02/01/2023
<b>International Equity</b>	<b>4,293,936</b>	<b>22.84</b>								
Non US Developed- Active	3,229,225	17.18	-3.58	-3.58	6.36	N/A	N/A	N/A	-1.31	02/01/2023
<i>MSCI AC World ex USA (Net)</i>			-3.77	-3.77	5.34	20.39	3.74	2.58	-2.56	02/01/2023
Non US Emerging	1,064,711	5.66	-3.22	-3.22	1.94	12.22	-2.01	0.36	2.57	11/01/2016
<i>MSCI Emerging Markets Index</i>			-2.79	-2.79	2.16	12.17	-1.34	0.94	3.62	11/01/2016
<b>Fixed Income</b>	<b>6,444,312</b>	<b>34.28</b>								
Core Plus Bonds	6,444,312	34.28	-1.69	-1.69	2.02	4.40	-3.63	1.19	1.96	07/01/2014
<i>Blmbg. U.S. Aggregate</i>			-3.23	-3.23	-1.21	0.64	-5.21	0.10	0.81	07/01/2014

Returns are net of fees.

Returns are expressed as percentages.

Plan Sponsor Peer Group Analysis

All Public Plans-Total Fund



	1 Quarter	Year To Date	Fiscal YTD	1 Year	3 Years	5 Years	7 Years
■ Total Fund	-2.89 (60)	6.11 (13)	-2.89 (60)	14.09 (7)	3.08 (84)	4.27 (84)	5.56 (85)
● Blended Benchmark	-3.33 (79)	5.96 (16)	-3.33 (79)	13.41 (12)	2.12 (91)	4.34 (81)	5.39 (87)
5th Percentile	-0.27	7.16	-0.27	14.23	8.56	7.35	8.30
1st Quartile	-1.83	5.46	-1.83	12.18	6.01	5.93	7.32
Median	-2.60	4.73	-2.60	10.67	4.83	5.30	6.66
3rd Quartile	-3.21	3.80	-3.21	9.21	3.56	4.61	5.91
95th Percentile	-3.82	2.23	-3.82	5.30	1.11	2.83	4.26
Population	486	465	486	458	435	419	398

Parenteses contain percentile rankings.  
 Calculation based on monthly periodicity.  
 Returns are net of fees and are expressed as percentages.

## Financial Reconciliation

QTR	Market Value As of 07/01/2023	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	19,357,958	-	(559,928)	18,798,030
Large Cap Index	6,618,140	-	(207,865)	6,410,275
SMID Cap Alternative	1,735,007	-	(85,501)	1,649,507
Non US Developed- Active	3,349,228	-	(120,003)	3,229,225
Non US Emerging	1,100,167	-	(35,457)	1,064,711
Core Plus Bonds	6,555,415	-	(111,104)	6,444,312

YTD	Market Value As of 01/01/2023	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	17,715,175	(19,467)	1,102,322	18,798,030
Large Cap Index	6,071,418	(410,418)	749,275	6,410,275
SMID Cap Alternative	-	1,634,611	14,895	1,649,507
Non US Developed- Active	-	2,995,258	233,967	3,229,225
Non US Emerging	1,094,951	(55,686)	25,445	1,064,711
Core Plus Bonds	5,032,983	1,332,589	78,739	6,444,312


## Financial Reconciliation

July 1, 2023 To September 30, 2023				
	Market Value As of 07/01/2023	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	19,357,958	-	(559,928)	18,798,030
Large Cap Index	6,618,140	-	(207,865)	6,410,275
SMID Cap Alternative	1,735,007	-	(85,501)	1,649,507
Non US Developed- Active	3,349,228	-	(120,003)	3,229,225
Non US Emerging	1,100,167	-	(35,457)	1,064,711
Core Plus Bonds	6,555,415	-	(111,104)	6,444,312

1 Year				
	Market Value As of 10/01/2022	Net Flows	Return On Investment	Market Value As of 09/30/2023
Total Fund	16,477,066	(24,361)	2,345,324	18,798,030
Large Cap Index	5,661,255	(410,564)	1,159,584	6,410,275
SMID Cap Alternative	-	1,634,611	14,895	1,649,507
Non US Developed- Active	-	2,995,258	233,967	3,229,225
Non US Emerging	994,673	(55,992)	126,030	1,064,711
Core Plus Bonds	4,917,838	1,330,547	195,926	6,444,312

Asset Allocation Compliance - Total Fund

	Asset Allocation (%)	Target Allocation (%)	Minimum Allocation (%)	Maximum Allocation (%)	Differences (%)
<b>Total Fund</b>	<b>100.0</b>	<b>100.0</b>	<b>N/A</b>	<b>N/A</b>	<b>0.0</b>
Domestic Equity	42.9	42.0	27.0	57.0	0.9
International Equity	22.8	23.0	8.0	38.0	-0.2
Fixed Income	34.3	35.0	15.0	55.0	-0.7



## Historical Hybrid Composition - Blended Benchmark

Allocation Mandate	Weight (%)
<b>Jul-2014</b>	
Russell 1000 Growth Index	20.0
Russell 1000 Value Index	20.0
Russell 2500 Index	10.0
MSCI EAFE (net)	10.0
Blmbg. Intermed. U.S. Government/Credit	35.0
90 Day U.S. Treasury Bill	5.0
<b>Jul-2015</b>	
Russell 3000 Index	36.0
MSCI AC World ex USA (Net)	19.0
Blmbg. U.S. Aggregate	45.0
<b>Dec-2021</b>	
Russell 3000 Index	42.0
MSCI AC World ex USA (Net)	23.0
Blmbg. U.S. Aggregate	35.0



## IMPORTANT DISCLOSURES

---

This material is for general information purposes only and is not intended to provide specific advice or a specific recommendation, as it was prepared without regard to any specific objectives or financial circumstances.

Investment advisory services are provided by PFM Asset Management LLC ("PFMAM"), an investment adviser registered with the U.S. Securities and Exchange Commission and a subsidiary of U.S. Bancorp Asset Management, Inc. ("USBAM"). USBAM is a subsidiary of U.S. Bank National Association ("U.S. Bank"). U.S. Bank is a separate entity and subsidiary of U.S. Bancorp. U.S. Bank is not responsible for and does not guarantee the products, services or performance of PFMAM. The information contained is not an offer to purchase or sell any securities. Additional applicable regulatory information is available upon request.

PFMAM professionals have exercised reasonable professional care in the preparation of this performance report. Information in this report is obtained from sources external to PFMAM and is generally believed to be reliable and available to the public; however, we cannot guarantee its accuracy, completeness or suitability. We rely on the client's custodian for security holdings and market values. Transaction dates reported by the custodian may differ from money manager statements. While efforts are made to ensure the data contained herein is accurate and complete, we disclaim all responsibility for any errors that may occur. References to particular issuers are for illustrative purposes only and are not intended to be recommendations or advice regarding such issuers. Fixed income manager and index characteristics are gathered from external sources. When average credit quality is not available, it is estimated by taking the market value weights of individual credit tiers on the portion of the strategy rated by a NRSRO.

It is not possible to invest directly in an index. The index returns shown throughout this material do not represent the results of actual trading of investor assets. Third-party providers maintain the indices shown and calculate the index levels and performance shown or discussed. Index returns do not reflect payment of any sales charges or fees an investor would pay to purchase the securities they represent. The imposition of these fees and charges would cause investment performance to be lower than the performance shown.

The views expressed within this material constitute the perspective and judgment of PFMAM at the time of distribution and are subject to change. Any forecast, projection, or prediction of the market, the economy, economic trends, and equity or fixed-income markets are based upon certain assumptions and current opinion as of the date of issue and are also subject to change. Some, but not all assumptions are noted in the report. Assumptions may or may not be proven correct as actual events occur, and results may depend on events outside of your or our control. Changes in assumptions may have a material effect on results. Opinions and data presented are not necessarily indicative of future events or expected performance.

For more information regarding PFMAM's services or entities, please visit [www.pfmam.com](http://www.pfmam.com).

© 2023 PFM Asset Management LLC. Further distribution is not permitted without prior written consent.



# Questa Independent School District

2556A Wildcat Road / P.O. Box 440 / Questa, NM 87556

District Office Phone: 575-586-0421 Fax: 575-586-0531

## **PETITION ADOPTED BY Questa Independent Schools GOVERNING BODY GIVING NOTICE OF INTENT TO (OFFER) DEPENDENT EMPLOYEE BENEFITS COVERAGES TO DOMESTIC PARTNERS**

The Governing Body of Questa Independent Schools (Petitioner) having affirmatively voted in a meeting noticed and conducted pursuant to the Open Meetings Act petitions the New Mexico Public Schools Insurance Authority (Authority) as follows:

The Petitioner will (offer) employee domestic partner benefits, as such lines of coverage are provided by the Authority to its employees; and

The Petitioner will (offer) insurance eligibility to domestic partners and will (offer) the employer's share of the insurance premiums for domestic partners; and

The Petitioner understands that to (offer) such employee domestic partner benefits pursuant to the rules of the Authority, there must be an affirmative choice to offer that coverage and notice of such choice to the Authority; and

The Petitioner understands that in (offering) employee domestic partner benefits, as provided by the Authority rule, it (may) or (may not) choose to pay an employer contribution toward the employee's insurance premium for such coverage; and

The Petitioner understands that in order for an employee to be eligible to participate in employee domestic partner benefits, an affidavit of domestic partnership must be provided in the form attached to this Petition as well as any further documentation required locally in support of the affidavit of domestic partnership;

THEREFORE, the members of the governing body of the Petitioner affirmatively choose to (offer) employee benefits to domestic partners as such benefits are provided by the Authority and hereby notifies the Authority of that choice. Petitioner hereby (offers) authorization of payment of employer contribution equal to that made for married employee benefits as an employer contribution and such payment is conditioned on submission of an Affidavit in proper form establishing a domestic partnership and providing the following information in support of the Affidavit:

Open enrollment will be offered till November 21<sup>st</sup> with an activation date of January 1<sup>st</sup> 2024.

The Questa Independent School District does not discriminate on the basis of race, religion, color, national origin, sex, disability, political beliefs, or age in its programs, activities, services or employment and provides equal access to the Boy Scouts and other designated youth groups. Questa Independent School District also prohibits the use of racial, ethnic, and/or sexual slurs, including sexual harassment. If you are an individual with a disability who is in need of a reader, amplifier, qualified sign language interpreter, or any other form of auxiliary aid or service to attend or participate in a school meeting or hearing, or if you wish to receive assistance or information regarding student grievances, language translations, Section 504 or Title IX, please contact the Superintendent's Office at least one week prior to the meeting or as soon as possible. Public documents, including the agenda and minutes, can be provided in the various accessible formats. The designated individual(s) to handle inquiries regarding the non-discrimination policies may be reached at 2556A Wildcat Road or 57 Sagebrush Road, 575-586-0421.

*This Petition must be submitted to the Authority for it to be effective. Domestic partner coverage shall be effective on the date set forth in the notice from the Authority to the Employer indicating the effective date of coverage for the domestic partner coverage.*

Members of the Governing Body of Questa Independent Schools

Name and Signature

Essequiel Romero



Jose Lovato



Michael R. Cordova

m R. Cordova

Juan Cisneros



Date:

11/1/2023

# Review of Historical Claims Experience

		Contract Period						
		UGU			Matrix			
		1/1/2017 - 12/31/2017	1/1/2018 - 12/31/2018	1/1/2019 - 12/31/2019	1/1/2020 - 12/31/2020	1/1/2021 - 12/31/2021	1/1/2022 - 12/31/2022	1/1/2023 – 9/30/2023
a	Number of Months	12	12	12	12	12	12	9
b	Number of Employees	22,692	21,119	20,703	21,716	21,356	21,146	21,442
c	PEPM Premium Rate	\$3.77	\$4.21	\$4.66	\$5.15	\$6.12	\$7.34	\$8.86
<b>d = a x b x c</b>	<b>Premium Paid</b>	<b>\$1,026,586</b>	<b>\$1,066,923</b>	<b>\$1,157,712</b>	<b>\$1,342,069</b>	<b>\$1,568,415</b>	<b>\$1,862,510</b>	<b>\$1,709,794</b>
e	Actual Claims Reimbursement <sup>(1)</sup>	\$679,517	\$0	\$884,161	\$1,216,123	\$82,752	\$880,748	TBA
f = 70% x d	Target Claims <sup>(2)</sup>	\$718,610	\$746,846	\$810,398	\$933,449	N/A	N/A	N/A
g = f - e	Excess Premium <sup>(2,3)</sup>	\$39,093	\$746,846	\$0	\$0	N/A	N/A	N/A
h = 50% x g	Experience Refund <sup>(2)</sup>	\$19,547	\$373,423	\$0	\$0	N/A	N/A	N/A
<b>i = (e + h) / d</b>	<b>Loss Ratio</b>	<b>68%</b>	<b>35%</b>	<b>76%</b>	<b>91%</b>	<b>5%</b>	<b>47%</b>	<b>TBA</b>

(1) Estimated claims reimbursement (based on data through September 2023)

(2) Experience refund provision removed from policy effective 1/1/2021

(3) If Actual Claims Reimbursement exceeds Target Claims, there is no Excess Premium



New Mexico Public Schools Insurance Authority

# Stop-Loss Insurance Request for Proposal (RFP) Analysis of Responses

Analysis for Coverage Effective January 1, 2024

December 6-7, 2023 / Debbie Donaldson, FSA, MAAA, Senior Vice President, Consulting Actuary



# Overview

- Segal, on behalf of the New Mexico Public Schools Insurance Authority (NMPSIA), solicited proposals from stop-loss insurers to cover **medical and prescription drug claimants over \$1,000,000** for an effective date of **January 1, 2024**
- Objective: Secure **market competitive financial terms**, while maintaining a **high-quality level of benefits and service for the plan**.
- Matrix Group Benefits, LLC (AccuRisk Solution, LLC) is the current provider of Specific Stop-Loss Insurance for NMPSIA
- Requested pricing proposals to include a **\$500,000 aggregating specific deductible** (current design) and any alternate offers
- Proposals were submitted by three vendors with two submitting Best and Final Offers (BAFO) proposals

# Key Stop Loss Provisions

- All vendors proposed an Individual Specific Deductible of \$1 million (*current design*)
- All vendors proposed an Aggregating Specific Deductible of \$500,000 (*current design*)
- All vendors proposed designs that covers Medical + Rx claims incurred in 24 months, paid in 12 months (*current design*)
  - Claims incurred between January 1, 2023 and December 31, 2024 (24 months)
  - Claims paid between January 1, 2024 and December 31, 2024 (12 months)
- No lasers listed by any vendor within their final proposals

# Review of Historical Claims Experience

		Contract Period						
		UGU			Matrix			
		1/1/2017 - 12/31/2017	1/1/2018 - 12/31/2018	1/1/2019 - 12/31/2019	1/1/2020 - 12/31/2020	1/1/2021 - 12/31/2021	1/1/2022 - 12/31/2022	1/1/2023 – 9/30/2023
a	Number of Months	12	12	12	12	12	12	9
b	Number of Employees	22,692	21,119	20,703	21,716	21,356	21,146	21,442
c	PEPM Premium Rate	\$3.77	\$4.21	\$4.66	\$5.15	\$6.12	\$7.34	\$8.86
<b>d = a x b x c</b>	<b>Premium Paid</b>	<b>\$1,026,586</b>	<b>\$1,066,923</b>	<b>\$1,157,712</b>	<b>\$1,342,069</b>	<b>\$1,568,415</b>	<b>\$1,862,510</b>	<b>\$1,709,794</b>
e	Actual Claims Reimbursement <sup>(1)</sup>	\$679,517	\$0	\$884,161	\$1,216,123	\$82,752	\$880,748	TBA
f = 70% x d	Target Claims <sup>(2)</sup>	\$718,610	\$746,846	\$810,398	\$933,449	N/A	N/A	N/A
g = f - e	Excess Premium <sup>(2,3)</sup>	\$39,093	\$746,846	\$0	\$0	N/A	N/A	N/A
h = 50% x g	Experience Refund <sup>(2)</sup>	\$19,547	\$373,423	\$0	\$0	N/A	N/A	N/A
<b>i = (e + h) / d</b>	<b>Loss Ratio</b>	<b>68%</b>	<b>35%</b>	<b>76%</b>	<b>91%</b>	<b>5%</b>	<b>47%</b>	<b>TBA</b>

(1) Estimated claims reimbursement (based on data through September 2023)

(2) Experience refund provision removed from policy effective 1/1/2021

(3) If Actual Claims Reimbursement exceeds Target Claims, there is no Excess Premium



# Financial Analysis: Overall Cost Comparison

Specific Stop-Loss Insurance	Current	Matrix – Preliminary	Matrix – BAFO	Sun Life <sup>1</sup> – Preliminary	Sun Life <sup>1</sup> – BAFO
Individual Specific Deductible	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
Aggregating Specific Deductible	\$500,000	\$500,000	\$500,000	\$500,000	\$500,000
Contract Basis (Incurred/Paid)	24/12	24/12	24/12	24/12	24/12
Covered Benefits	Med/Rx	Med/Rx	Med/Rx	Med/Rx	Med/Rx
Specific Composite Premium Rate (PEPM)	\$8.86	\$9.95	\$9.95	\$14.16	\$13.56
Total Annual	\$2,283,000	\$2,564,000	\$2,564,000	\$3,648,000	\$3,494,000
\$ Difference from Current		\$281,000	\$281,000	\$1,365,000	\$1,211,000
% Difference from Current		12.3%	12.3%	59.8%	53.0%
Rate Guarantee		12 months	12 months	12 months	12 months

1. Sun Life also offering health advocacy and care navigation services with an additional cost.

Assumptions:  
Total Enrollment: 21,470

# Offeror Response Highlights

Questions	Matrix	Sun Life
<p><b>1.11</b> If any of the medical plan administrators change at any point in the policy period, what impact would that have to your fees?</p>	None	<i>None</i>
<p><b>2.9</b> Vendor attests to meeting all applicable HIPAA EDI, Privacy, Security, and HITECH requirements and agrees to hold NMPSIA harmless for breaches that are the result of the vendor’s actions. Further, you agree to perform all of the duties associated with breach notification and assume financial responsibilities for the breach notice and notify plan participants if there is a breach and you will pay for 24 months of identity theft repair and credit monitoring services for those plan participants impacted by the breach. As it relates to an ASO arrangement, for the service(s) specified in this proposal, the vendor will become a HIPAA Business Associate of NMPSIA.</p>	Yes	Yes
<p><b>2.13</b> Claims and Appeals Regulations: Do you agree that your systems, internal operations, correspondence, and services will be compliant with ERISA Claims and Appeals Regulations (as applicable) and NMPSIA’s plan document?</p>	Yes	Yes
<p><b>2.18</b> Recoveries: 100% of all validated recoveries made through the vendor, its subcontractors, or NMPSIA audits will be credited to NMPSIA’s experience.</p>	Yes	Yes
<p><b>2.20</b> Claim Run Out: Do you agree to offer NMPSIA the ability to process run out claims beyond the termination date for claims incurred during the policy period?</p>	Yes	Yes

*Response updated after requesting clarification to question*

# Offeror Response Highlights (cont'd)

Questions	Matrix	Sun Life
5.4 Are there any exclusions, limitations, or different recognized charge limits under your contract(s) that are covered expenses, as described in the plan document?	No	No, we mirror the plan document
5.13 Do you require eligibility files, or do you rely on verification of eligibility at the time of a specific claim?	At time of claim	<i>At time of claim</i>
5.16 Does your policy cover gene therapy drugs such as Luxturna and Zolgensma?	Yes	Yes
5.33 Do you agree to provide NMPSIA or it's designated consulting firm monthly reports showing claimant name, carrier/administrator (BCBSNM/Presbyterian/Cigna), plan (High/Low/EPO), eligible status (active/COBRA/etc.), amount submitted, amount pending, amount paid, and the amount denied?	Yes	Yes
5.39 Do you agree to provide an annual reconciliation showing month by month the attachment point vs eligible expense?	Yes	<i>Yes</i>
5.44 Are there any additional services or programs you will provide to NMPSIA at no additional cost?	No	No New Laser with 50% Rate Cap, Advanced Funding
5.46 Confirm your rates and terms for your policy include Active and Retirees (if applicable)?	Actives & Retirees	Actives & Retirees

*Response updated after requesting clarification to question*

# Proposer Background and Experience

- Vendors provided their financial strength ratings from the following ratings agencies (3.16)

	Matrix	Sun Life
AM Best	A+	A+
Standard & Poor's	Did not provide	AA
Moody's	Did not provide	Aa3

**Investment Grade or Secure:**

<b>AAA (A++)</b>	Companies rated AAA have the highest rating assigned. Capacity to pay interest and repay principal is extremely strong.
<b>AA (A+)</b>	Companies rated AA have a very strong capacity to pay interest and repay principal and differ from the highest rated issuers only to a small degree.
<b>A (A, A-)</b>	Companies rated A have a strong capacity to pay interest and repay principal, although they are somewhat more susceptible to adverse changes in economic conditions than those in higher rated categories.
<b>BBB (B++, B+)</b>	Companies rated BBB are regarded as having an adequate capacity to pay interest and repay principal, however, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity to pay interest and repay principal.

**Below Investment Grade or Vulnerable:**

<b>BB (B) B (B-) CCC (C++, C+) CC (C, C-)</b>	Companies rated BB, B, CCC and CC are regarded, on balance, as speculative with respect to their credit worthiness. While such companies may have some protective characteristics, uncertainties and major risk exposure or adverse conditions outweigh them.
<b>R; NR</b>	The rating R is reserved for companies who “have experienced a REGULATORY ACTION regarding solvency.” The rating NR indicates that the insurer’s financial solvency is not rated.

# Thank You

**Debbie Donaldson, FSA, MAAA**  
*Senior Vice President, Consulting Actuary*  
[ddonaldson@segalco.com](mailto:ddonaldson@segalco.com)  
(303) 908-9031



Scan this QR code to  
receive emails from  
Segal, personalized for  
your interests/industry.



# | Appendix

# Leveraged Trend Illustration

**Terms:** \$1,700,000 Individual Claimant 2023  
\$1,000,000 Individual Stop Loss Level  
\$500,000 Aggregating Specific Deductible

	2023	2024	
Total Individual Claim	\$1,700,000	\$1,785,000	+ 5%
Individual Stop Loss	\$1,000,000	\$1,000,000	
<u>Aggregating Specific</u>	<u>\$500,000</u>	<u>\$500,000</u>	
<b>Reimbursement</b>	<b>\$200,000</b>	<b>\$285,000</b>	<b>+ 43%</b>

- Even though the individual claim increased by 5% in 2024, from \$1,700,000 to \$1,785,000, the reimbursement increased by 43%, from \$200,000 to \$285,000.
- This type of leveraging occurs with any type of fixed co-payments or fixed deductibles.

Employers can mitigate leveraged trend by increasing the Individual Stop Loss level or Aggregating Specific Deductible by marketplace trend. However, the Employer would take on additional claims risk as a result.


# Aggregating Specific Stop Loss Examples

- **Illustration #1:** Three claimants whose total claims exceed the Individual Deductible:

- Claimant A: \$1,250,000
- Claimant B: \$1,100,000
- Claimant C: \$1,050,000

- The total excess claims are

\$250,000
\$100,000
+ \$ 50,000
<hr/>
\$400,000



- Since \$400,000 is less than the \$500,000 Aggregating Specific Deductible, there are **NO Stop Loss Reimbursements**.




# Aggregating Specific Stop Loss Examples (cont'd)

- **Illustration #2:** Three claimants whose total claims exceed the Individual Deductible:
  - Claimant A: \$1,350,000
  - Claimant B: \$1,250,000
  - Claimant C: \$1,150,000

- The total excess claims are
 

\$350,000
\$250,000
+ \$150,000
<hr/>
\$750,000



- Since \$750,000 is greater than the \$500,000 Aggregating Specific Deductible, there are
 

\$750,000
- \$500,000
<hr/>
<b>\$250,000 in Stop Loss Reimbursements.</b>



**NEW MEXICO PUBLIC SCHOOLS  
INSURANCE AUTHORITY  
Office of Executive Director**

**BOARD OF DIRECTORS**

**Patrick Sandoval**  
Executive Director

**Martha Quintana**  
Deputy Director

410 Old Taos Highway  
Santa Fe, New Mexico 87501  
1-800-548-3724 or 505-988-2736  
505-983-8670 (fax)

- NM School Boards Association
- NM Superintendents Association
- Public Education Commission
- NM School Administrators
- NM National Education Association
- American Federation of Teachers N.M.
- Governor Appointees
- Educational Institutions at Large

December 7, 2023

Stephanie Anthony  
Client Director  
United Concordia Companies, Inc.  
4401 Deer Path Road  
Harrisburg, PA 17110

RE: Amendment - Effective January 1, 2024, to June 30, 2024  
Professional Services Agreement for Dental Coverage,  
United Concordia Companies, Inc.  
Agreement No. 20-014MG-PSIA05

Dear Ms. Anthony:

This letter shall constitute an Amendment to the above-captioned Agreement between the New Mexico Public Schools Insurance Authority, hereinafter referred to as the "Agency," and United Concordia Companies, Inc., hereinafter referred to as the "Contractor" and is effective as of the dates shown herein.

The Agency and Contractor entered into a Professional Services Agreement for Dental Coverage ("Agreement") effective June 30, 2020. The Agency and Contractor wish to amend their Agreement with the amendments set out herein.

1. Pursuant to Exhibit B of the Agreement, "ADMINISTRATIVE SERVICE FEES" the administrative fee payable to the Contractor under the Agreement for the period of January 1, 2024, through June 30, 2024, shall be \$1.65 PMPM.
2. It is agreed that the above captioned Agreement and any duly authorized and executed amendments thereto are hereby extended for the term through June 30, 2024.
3. This Amendment has been signed via DocuSign.

**New Mexico Public Schools  
Insurance Authority**

By:

---

Alfred A. Park  
Board President

**United Concordia Companies, Inc.**

By:

---

Stephanie Anthony  
Client Director



New Mexico Public Schools Insurance Authority

# Healthcare Dashboard

**Active & Grandfathered Retiree Members**

**Current Period: July 2022 – June 2023 (incurred)**

**Prior Period: July 2021 – June 2022 (incurred)**

December 6 & 7, 2023

# Key Findings and Suggestions


## Key Findings

- Medical trends are slightly lower than expected. Per member per month increases are driven by higher utilization of ER Visits, outpatient surgery and pharmacy within the medical benefit offset by lower inpatient and professional costs. Members are using providers in lower cost settings; there may be opportunities to moderate emergency room utilization.
- Pharmacy trends are significantly higher than expected; increases are more than double expectations. These are driven by the cost of drugs utilized; including higher Specialty utilization and more use of brand name drugs to treat chronic conditions like diabetes. There are shifts to 90-day fills which may improve adherence.
- GLP-1 Anti-Diabetic medication costs and prevalence are consistently higher than Segal data warehouse clients' experience. GLP-1 medications increased more than 50% PMPM and over 40% PMPM since 2019. Utilization for these medications is increasing at a similar pace and use for weight loss is contributing to this trend.
- Compared to other public sector clients in the SHAPE data warehouse, NMPSIA facility utilization is lower and trending toward providers in lower cost settings (i.e., urgent care, outpatient surgery). However, emergency room utilization is increasing and higher than benchmarks.
- Experience for members with select chronic conditions worsened due to large claimant activity – including cancers and chronic conditions. The proportion of members with Diabetes is higher than last year and Segal benchmarks. While A1c testing is stable, there is lower compliance for nephropathy and retinopathy. There is room for improvement on medication adherence for patients with Coronary Artery Disease and preventive cancer screenings continue to improve.

## Suggestions

- Monitor prescription patterns for Specialty, diabetes and weight loss to ensure appropriate utilization of higher cost medications and to verify rebate guarantees and realization of manufacturer coupons.
- Consider future review of the pharmacy utilization within the medical plan to verify appropriate use and identify opportunities for possible lower cost alternatives.
- Monitor utilization of GLP-1 medications for appropriate diagnoses and consideration of any utilization management or benefit program changes. Evaluate net plan impact of rebates on total pharmacy spend.

### 1. Principal Financial Trends—Plan Paid



### 2. Claims Summary

Place of Service	Current Period			Prior Period			% Change in PMPM
	Total Paid Amount	Total Paid PMPM	% of Total	Total Paid Amount	Total Paid PMPM	% of Total	
Outpatient Hospital <sup>1</sup>	\$110,093,100	\$204.18	28.6%	\$97,042,590	\$178.51	27.2%	14.4%
Inpatient Hospital	\$63,448,900	\$117.67	16.5%	\$68,304,588	\$125.64	19.1%	-6.3%
Professional	\$53,428,815	\$99.09	13.9%	\$55,809,348	\$102.66	15.6%	-3.5%
Emergency Room	\$34,004,713	\$63.06	8.8%	\$29,350,875	\$53.99	8.2%	16.8%
Urgent Care	\$1,645,090	\$3.05	0.4%	\$1,327,025	\$2.44	0.4%	25.0%
Drugs (Medical Benefit)	\$27,103,311	\$50.27	7.0%	\$23,322,634	\$42.90	6.5%	17.2%
All Others <sup>2</sup>	\$6,233,368	\$11.56	1.6%	\$6,317,991	\$11.62	1.8%	-0.5%
<b>Total Medical</b>	<b>\$295,957,297</b>	<b>\$548.88</b>	<b>76.8%</b>	<b>\$281,475,051</b>	<b>\$517.76</b>	<b>78.8%</b>	<b>6.0%</b>
<b>Total Rx<sup>3</sup></b>	<b>\$89,501,809</b>	<b>\$165.99</b>	<b>23.2%</b>	<b>\$75,514,064</b>	<b>\$138.91</b>	<b>21.2%</b>	<b>19.5%</b>
<b>Total Paid</b>	<b>\$385,459,105</b>	<b>\$714.87</b>	<b>100.0%</b>	<b>\$356,989,115</b>	<b>\$656.67</b>	<b>100.0%</b>	<b>8.9%</b>
<b>Member Paid</b>	<b>\$49,482,781</b>	<b>\$91.77</b>	<b>12.8%</b>	<b>\$45,812,736</b>	<b>\$84.27</b>	<b>12.8%</b>	<b>8.9%</b>
<b>Plan Paid</b>	<b>\$335,976,324</b>	<b>\$623.10</b>	<b>87.2%</b>	<b>\$311,176,379</b>	<b>\$572.40</b>	<b>87.2%</b>	<b>8.9%</b>

### Observations

- Total Medical Per Member Per Month (PMPM) increased 6.0% when comparing July 2022-June 2023 to July 2021-June 2022 incurred claims, lower than the projected budgets at 6.5% and Segal trend of 7.4%<sup>4</sup>
  - Outpatient services experienced a large increase at 14.4% on a PMPM basis. These were driven by increased surgery utilization and cost.
  - Drugs within the medical benefit increase significantly for the second year in a row. SEE SPOTLIGHT?
  - Emergency Room experienced another increase of nearly 17%; while more cost driven, utilization continues to increase and is higher than pre-pandemic levels.
- Rx costs continue a steady increase; at 9.0% on a PMPM basis and is driven by costs of drugs utilized (see Panels 7 & 8). This is significantly higher than projection assumptions at 9% and the projected Segal trend of 9.8%<sup>4</sup>.

<sup>1</sup> “Outpatient Hospital” includes Ambulatory Surgical Centers

<sup>2</sup> “All Others” includes Ancillary type services such as Home, Ambulance, and DME.

<sup>3</sup> Total Rx does not account for rebates.

<sup>4</sup> Projected Segal trend is per the <https://segalnet/media/3488206/2024-segal-health-plan-cost-trend-survey.pdf>

### 3. Key Healthcare Performance Metrics

Category	Current Period	Prior Period	Change	Norm <sup>1</sup>	Comparison to Norm
Avg Membership Per Month	44,934	45,303	-0.8%	N/A	N/A
Office Visits per 1,000	4,816	4,550	5.8%	4,267	12.9%
Preventive Office Visits per 1,000	699	668	4.6%	N/A	N/A
Inpatient Admissions Per 1,000	42	43	-0.3%	45	-5.9%
Inpatient Days per 1,000	185	215	-13.7%	234	-20.6%
Average Inpatient Day Cost	\$7,449	\$7,098	5.0%	\$6,662	11.8%
Average Cost per Admission	\$32,558	\$35,819	-9.1%	\$34,534	-5.7%
Readmission within 30 days per 1000 <sup>2</sup>	70	60	16.8%	N/A	N/A
ER Visits per 1,000	208	195	6.5%	195	6.4%
Rx Scripts per 1,000	11,132	12,189	-8.7%	14,578	-23.6%

#### Observations

- Inpatient metrics are generally down when compared to the prior period; lower volume and/or severity for acute cases of COVID-19 and digestive-related admissions.
- Office Visits per 1,000 increased by nearly 6%, driven by a 16% increase in Behavioral health office visits. Preventive visits and preventive cancer screens are also improving.
- Rx Scripts per 1,000 decreased 8.7%; utilization is lower than other public sector SHAPE groups. There was a shift to Retail 90 and an increase in average days' supply which is higher than normative data.
- ER Visits per 1,000 increased by again; by 6.5%. This is now higher than other SHAPE groups and pre-pandemic levels. There also appears to be a slight increase in utilization that could be treated in a lower cost setting.

<sup>1</sup> SHAPE database, public sector norms, based upon 2021 experience; adjusted for group-specific age and gender mix.

<sup>2</sup> Readmissions are defined as a subsequent hospital admission within 30 days following an original admission. Patients were followed across the same and different hospitals. All-cause readmissions were examined; thus, readmissions may or may not include conditions that were listed as the principal diagnosis during the index stay. Also may not reflect planned readmissions or step-down units.

<sup>3</sup> Members with co-morbidities and their corresponding claims are combined in each applicable category.

<sup>4</sup> Reflects the ratio of PMPY costs of members with the chronic condition to the total enrolled population.

### 4. Major Conditions—Prevalence and Cost (with Conditions)

Chronic Condition <sup>3</sup>	Current Period							% Change	
	Members	% of Total	Norm <sup>1</sup>	Medical Claims	% of Total	PMPY	PMPY Comparison <sup>4</sup>	Prevalence	PMPY
1. Diabetes	4,410	9.8%	7.7%	\$60,027,951	20.3%	\$13,612	207%	1.4%	7.9%
2. CAD	1,062	2.4%	2.9%	\$33,601,448	11.4%	\$31,640	480%	0.0%	-0.6%
3. Asthma	4,400	9.8%	8.2%	\$40,647,934	13.7%	\$9,238	140%	1.3%	1.1%
4. COPD	282	0.6%	0.7%	\$8,447,408	2.9%	\$29,955	455%	0.1%	-8.8%
5. Hypertension	9,833	21.9%	22.5%	\$126,714,375	42.8%	\$12,887	196%	0.6%	6.7%
6. Mental Health	9,838	21.9%	34.9%	\$86,329,959	29.2%	\$8,775	133%	0.8%	13.4%
7. SUD	860	1.9%	3.0%	\$12,002,842	4.1%	\$13,957	212%	0.1%	23.2%
8. CHF	168	0.4%	0.5%	\$8,411,746	2.8%	\$50,070	760%	0.0%	-22.2%
<b>Totals (unique)</b>	<b>20,125</b>	<b>44.8%</b>		<b>\$193,911,222</b>	<b>65.5%</b>	<b>\$9,635</b>	<b>146%</b>	<b>1.9%</b>	<b>6.7%</b>

#### Observations

- In total, 44.8% of members have been identified with at least one of the measured conditions. This is a nearly 2%-point increase in the prevalence of these conditions within the group. The medical costs for these members represents 65.5% of total medical costs for the population.
- Members with diabetes increased in prevalence and cost over the prior period. NMPSIA has a higher prevalence of diabetes than other public sector clients in SHAPE. This was driven by an increased volume of diabetics with large claims; including cancer and ESRD as driving diagnoses.
- Members with behavioral health conditions experienced large claims primarily due to other conditions. An underlying comorbidity with cancer as a primary condition drove the cost increases.

### 5. High Risk High Cost Analysis (High Cost by Condition)

Chronic Condition for High Cost Claimants <sup>1</sup>	Current Period			Prior Period			% Change	
	Members	% Within Condition	PMPY	Members	% Within Condition	PMPY	Prev	PMPY
1. Diabetes	507	11.5%	\$83,314	398	10.4%	\$81,323	1.1%	2.4%
2. CAD	280	26.4%	\$101,130	275	25.3%	\$106,577	1.0%	-5.1%
3. Asthma	350	8.0%	\$64,430	292	7.6%	\$68,729	0.4%	-6.3%
4. COPD	61	21.6%	\$114,440	60	25.0%	\$113,799	-3.4%	0.6%
5. Hypertension	1,050	10.7%	\$83,466	960	10.0%	\$81,973	0.7%	1.8%
6. CHF	64	38.1%	\$119,549	72	42.1%	\$141,946	-4.0%	-15.8%
7. Breast Cancer	98	26.1%	\$116,208	94	26.2%	\$96,702	-0.1%	20.2%
8. Colon Cancer	33	35.9%	\$152,844	28	36.8%	\$156,688	-1.0%	-2.5%
9. Prostate Cancer	29	24.0%	\$87,696	32	24.2%	\$79,360	-0.3%	10.5%
<b>Totals (unique)</b>	<b>1,365</b>		<b>\$82,538</b>	<b>1,235</b>		<b>\$80,622</b>	<b>0.4%</b>	<b>2.4%</b>

#### Observations

- The prevalence of high-cost claimants with a chronic condition (i.e. total medical claims exceeding \$25K) slightly increased by 0.4%-points from the prior year. The claims for members exceeding the \$25K threshold increased 2.4% overall from the prior year; driven by severity in higher cases. Cancer and ESRD cases increased and contributed to cost increases for members with chronic conditions.
- Despite a reduction in prevalence, Breast and Colon Cancer costs increased at significantly. Care gap compliance is improving; but higher severity cases reinforce the importance of early detection.

<sup>1</sup> High Cost Claimants are above \$25,000 (does not include Rx claims).  
<sup>2</sup> Source: SHAPE database, public sector norms, based upon 2021 experience.

### 6. Clinical Quality Performance

Chronic Conditions	Clinical Quality Metrics	Population	Current Period	Prior Period	SHAPE Public Sector <sup>2</sup>
Diabetes	At least 1 hemoglobin A1C tests in last 12 months	4,410	80.9%	81.1%	79.5%
	Annual screening for diabetic nephropathy	4,410	54.6%	57.4%	63.1%
	Annual screening for diabetic retinopathy	4,410	17.9%	19.3%	35.9%
CAD	Patients currently taking an ACE-Inhibitor or ARB Drug	1,062	43.9%	46.6%	40.1%
	Patients currently taking a statin	1,062	61.9%	63.0%	69.7%
Hyperlipidemia	Total cholesterol testing in last 12 months	10,929	70.1%	64.0%	76.2%
COPD	Spirometry testing in last 12 months	282	22.3%	16.0%	28.4%
Asthma	Patients with inhaled corticosteroids or leukotriene inhibitors in the last 12 months	4,400	72.4%	82.4%	76.9%
Preventive Screening	Cervical cancer	20,678	23.7%	24.6%	37.8%
	Breast cancer	13,101	40.9%	40.1%	49.4%
	Colorectal cancer	14,926	35.2%	33.3%	38.1%
	Prostate cancer	6,497	40.9%	39.8%	48.4%

#### Observations

- Increased prevalence of Diabetics; compliance is down slightly but may be due to timing. Nephropathy and retinopathy testing are consistently down and lower than norms. Given proportions of larger claimants with diabetes and/or ESRD; ensure members are managed and adherent.
- Members with CAD have experienced decreases in compliance rates when compared to the prior period; concerning given circulatory conditions are the primary drivers for inpatient costs.
- Preventive cancer screenings within NMPSIA range from 23.7% to 40.9%. Other than cervical screening, preventive cancer screening rates continue to improve and trend closer to other SHAPE clients.
- Encourage members with diabetes to engage with CVS' offering and care management for all aspects of care with a goal of mitigating disease progression.



**7. Summary of Prescription Drug Expenses**

Category	Non-Specialty		Specialty		Total		
	Current Period	Change	Current Period	Change	Current Period	Prior Period	Change
Total Cost <sup>1</sup>	\$48,579,645	16%	\$40,922,164	21.2%	\$89,501,809	\$75,514,064	18.5%
% of Total Costs	54.3%	-1.8%	45.7%	2.2%			
Total Scripts	490,224	-9.9%	9,962	21.7%	500,186	552,190	-9.4%
% of Total Scripts	98.0%	-0.5%	2.0%	34.3%			
Avg Cost PMPM	\$90.10	17.3%	\$75.89	22.2%	\$165.99	\$138.91	19.5%
Avg Cost Per Rx	\$99.10	29.1%	\$4,108	-0.4%	\$178.94	\$136.75	30.8%
Number of Scripts PMPM	0.91	-9.1%	0.02	22.7%	0.93	1.02	-8.7%
Generic Dispensing Rate	83.7%	-2.2%	41.4%	-19.6%	82.9%	85.1%	-2.6%
Member Cost %	7.9%	-19.3%	24.7%	19.8%	15.6%	14.6%	6.5%

**Observations**

- Total prescription drug cost increased 19.5% PMPM driven by an increase in non-specialty drug cost and utilization of higher cost Specialty medications.
- Total scripts decreased when compared to prior period. However, average days' supply increased as there was a shift in the number of prescriptions filled for 90 days at retail. There was still in overall increase in the average cost per day.
- Average cost per Rx increased by more than 30% and average cost per day at nearly 12%. While the cost per Specialty script did not increase significantly, the higher utilization of that class contributed to increased cost per script.
- The generic dispensing rate decreased slightly and is now just under 83%. Continued marketing for new drugs is ever-increasing; remind members to use lower cost generics wherever possible. Increased utilization for medications to treat autoimmune, psoriasis and multiple sclerosis also contribute to a lower generic proportion as many of these are Specialty and/or have very limited generic options.

<sup>1</sup> Total Cost does not account for rebates nor Specialty manufacturer coupon programs. Specialty drugs are based upon a Segal defined list and may not exactly match that of the Pharmacy Benefit Manager

### 8. Prescription Drug Cost Management Analysis

Rank	Top 10 Indications	Prev Rank/ Movement		Current Period				Prior Period				% Change		
				Total Scripts <sup>1</sup>	Total Cost <sup>2</sup>	Generic Fill Rate	PMPM	Total Scripts <sup>1</sup>	Total Cost <sup>2</sup>	Generic Fill Rate	PMPM	Total Scripts*	Total Cost/Rx <sup>2</sup>	PMPM
1	Diabetes	1	-	36,460	\$20,387,333	44.3%	\$37.81	39,112	\$16,999,975	52.1%	\$31.27	-6.8%	28.6%	20.9%
2	Autoimmune Disease	2	-	3,547	\$16,269,436	23.6%	\$30.17	2,539	\$14,410,854	35.6%	\$26.51	39.7%	-19.2%	13.8%
3	Oncology	3	-	2,938	\$7,955,953	76.5%	\$14.75	3,101	\$6,355,256	84.9%	\$11.69	-5.3%	32.1%	26.2%
4	Psoriasis	4	-	672	\$5,995,223	9.8%	\$11.12	463	\$4,136,716	25.7%	\$7.61	45.1%	-0.1%	46.1%
5	Asthma/COPD	5	-	23,060	\$3,351,724	77.6%	\$6.22	24,153	\$3,315,047	78.4%	\$6.10	-4.5%	5.9%	1.9%
6	Multiple Sclerosis/Neuromuscular Disorders	6	-	371	\$2,663,592	37.5%	\$4.94	291	\$2,379,732	25.4%	\$4.38	27.5%	-12.2%	12.8%
7	Viral Infections/HIV AIDS	7	-	814	\$2,312,983	26.2%	\$4.29	876	\$2,257,376	28.5%	\$4.15	-7.1%	10.3%	3.3%
8	Rare Disorders	18	▲ 10	512	\$2,267,680	73.4%	\$4.21	507	\$851,176	90.9%	\$1.57	1.0%	163.8%	168.6%
9	Diabetic Supplies/Monitoring	11	▲ 2	7,051	\$2,230,416	0.0%	\$4.14	5,804	\$1,421,091	0.0%	\$2.61	21.5%	29.2%	58.2%
10	Skin Disorders	9	▼ 1	9,303	\$1,934,802	93.7%	\$3.59	8,775	\$1,778,171	95.1%	\$3.27	6.0%	2.6%	9.7%
<b>Total Top 10:</b>				<b>84,728</b>	<b>\$65,369,141</b>	<b>55.1%</b>	<b>\$121.23</b>	<b>85,621</b>	<b>\$53,905,393</b>	<b>60.9%</b>	<b>\$99.16</b>	<b>-1.0%</b>	<b>22.5%</b>	<b>22.3%</b>

#### Observations

- Diabetes continues to be the leading disease indication with a PMPM of \$37.81, which is a 20.9% pmpm increase over the prior period. The high drug cost for the average diabetic is another reason to manage this chronic population aggressively. In addition, reminding members to utilize generic options as much as possible can mitigate cost trend. New use of Mounjaro and increased use of GLP-1 medications contributes to the cost increase in this category.
- Psoriasis and auto-immune diseases experienced significant increases in total scripts at more than 40% over the prior period. Utilization continues to shift from lower cost Cosentyx to higher cost options like Skyrizi, Stelara and Taltz. Significantly higher utilization of Enbrel, Humira and Rinvoq for autoimmune disease drove these changes. To the extent manufacturer coupons are utilized, this may have resulted in offsetting savings.
- Rare disorders experienced cost increases due to selected medications; particularly kidney failure and blood disorders.
- Oncology cost increases are driven by a utilization shift to Specialty medications; the proportion of that class increased 9 percentage points and the average cost per script for those medications is about five times the average for oncology medications overall.

<sup>1</sup> Both 30-day and 90-day dispensed drugs are counted as one (1) script.


<sup>2</sup> Total cost does not account for rebates.

**9. Distribution of Plan Paid Claims**

**% of Members**


**% of Medical Plan Cost**

**PMPM**



# GLP-1 Medications % Change in Allowed PMPM for Anti-Diabetic Agents


Anti-Diabetic GLP-1 Prescription Drugs  
Rolling 12-Month Trend



- Year-over-year trends for GLP-1 medications within NMPSIA were higher than the approximately 50% for SHAPE’s BoB as of June 2023. PMPM cost trend for NMPSIA has steadily increased since the beginning of FY2023 and is getting stronger.
- An earlier examination of GLP-1 utilization in the NMPSIA population indicated a steady growth in diabetic members using GLP-1 drugs and 8% higher in CY 2022.
- For plans that do not cover GLP-1s for weight-loss, off-label utilization in this class is typically 5-15% of utilizers, mostly due to insufficient prior authorization requirements implemented by most PBMs. Ozempic and Mounjaro are the two main drugs experiencing off-label utilization.

Source: SHAPE Data Warehouse

## GLP-1 Medications Allowed PMPM by Disease Indication




- Per member per month (PMPM, member includes covered dependents) spend on anti-diabetic GLP-1s reached \$27.14 as of June 2023, nearly double that of the SHAPE BoB and over the 75<sup>th</sup> percentile of other groups.
- PMM costs were increasing at a slightly lower rate than the SHAPE BoB, but increased significantly through June 2023.

Source: SHAPE Data Warehouse


## SPOTLIGHT ON

### Diabetic Medications Annual Spend and Utilization

Diabetic Pharmacy Utilization and Spend



Members and Prescriptions





- Diabetic medications account for significant total pharmacy spend (>20%), which is partially driven by an increase in the cost of medications utilized and higher proportions of the population utilizing these medications.
  - 2023 estimated<sup>1</sup> total allowed is on pace to increase nearly 60% from that of 2019 - \$21.0M compared to \$13.3M
  - 2023 estimated<sup>1</sup> total GLP-1 allowed is on pace to increase more than 40% from that of 2019 - \$10.2M compared to \$3.2M
- The number of diabetic medication users per 1,000 has increased from 77.5 per 1,000 in 2019 to 90.7 in 2022 (higher increases in recent periods).
- GLP-1 total allowed has more than doubled from 2019 to 2022, from \$3.2M to over \$7.0M – an increase of 30.1% on an annualized basis. The number of GLP-1 users has also increased approximately more than 30% over the same period.

Source: NMPSIA Diabetic Medications & Obesity Spotlight (August 15, 2023) using experience through March 2023; costs are annualized for CY 2023

### GLP-1 Medications Prior Utilization and Weight Loss Use

Diabetic vs Weight Loss GLP-1 Cost and Utilization



- Overall, 8.1% had no confirmed history of diabetes, but a confirmed history of obesity, this rate was highest in:
  - **13.9% of Ozempic** utilizers
  - **20.0% of Mounjaro** utilizers
  - **7.4% of Victoza** utilizers
- Utilization and costs related to weight loss-specific GLP-1 medications (mainly Wegovy) increased significantly in 2022 and continued through 2023 YTD after little to no utilization previously. Weight loss GLP-1s only came into experience during 2021, but are growing rapidly and estimated to more than quadruple during 2023. Diabetes GLP-1s accounted for nearly all GLP-1 spend (99%); estimated to comprise 83% 2023 YTD (data incurred through May)

Source: NMPSIA Diabetic Medications & Obesity Spotlight (August 15, 2023) using experience through March 2023; costs are annualized for CY 2023


# | Appendix

## **Dashboards by Administrator**

- Presbyterian
- BlueCross BlueShield of New Mexico (BCBSNM)
- CIGNA



### 1. Principal Financial Trends—Claims Cost



### 2. Claims Summary

Place of Service	Current Period			Prior Period			% Change in PMPM
	Total Paid Amount	Total Paid PMPM	% of Total	Total Paid Amount	Total Paid PMPM	% of Total	
Outpatient Hospital	\$45,804,078	\$188.25	28.8%	\$38,917,218	\$157.61	27.2%	19.4%
Inpatient Hospital	\$29,503,245	\$121.26	18.5%	\$29,540,615	\$119.64	20.7%	1.4%
Professional	\$22,349,363	\$91.86	14.0%	\$22,735,646	\$92.08	15.9%	-0.2%
Emergency Room	\$15,692,467	\$64.50	9.9%	\$12,917,088	\$52.31	9.0%	23.3%
Urgent Care	\$1,448,009	\$5.95	0.9%	\$1,139,625	\$4.62	0.8%	28.9%
Drugs (Medical)	\$7,351,846	\$30.22	4.6%	\$6,597,799	\$26.72	4.6%	13.1%
All Others <sup>1</sup>	\$2,364,332	\$9.72	1.5%	\$2,265,684	\$9.18	1.6%	5.9%
<b>Total Medical</b>	<b>\$124,513,339</b>	<b>\$511.75</b>	<b>78.2%</b>	<b>\$114,113,676</b>	<b>\$462.16</b>	<b>79.8%</b>	<b>10.7%</b>
<b>Total Rx</b>	<b>\$34,798,651</b>	<b>\$143.02</b>	<b>21.8%</b>	<b>\$28,934,945</b>	<b>\$117.19</b>	<b>20.2%</b>	<b>22.0%</b>
<b>Total Paid</b>	<b>\$159,311,990</b>	<b>\$654.77</b>	<b>100.0%</b>	<b>\$143,048,621</b>	<b>\$579.34</b>	<b>100.0%</b>	<b>13.0%</b>
<b>Member Paid</b>	<b>\$21,334,249</b>	<b>\$87.68</b>	<b>13.4%</b>	<b>\$20,196,460</b>	<b>\$81.79</b>	<b>14.1%</b>	<b>7.2%</b>
<b>Plan Paid</b>	<b>\$137,977,742</b>	<b>\$567.08</b>	<b>86.6%</b>	<b>\$122,852,161</b>	<b>\$497.55</b>	<b>85.9%</b>	<b>14.0%</b>

### 3. Key Healthcare Performance Metrics

Category	Current Period	Prior Period	Change	Norm <sup>2</sup>	Comparison to Norm
Avg Membership Per Month <sup>3</sup>	20,276	20,576	-1.5%	N/A	N/A
Office Visits per 1,000	4,288	4,181	2.6%	4,169	2.9%
Preventive Visits per 1,000	623	602	3.6%	N/A	N/A
Inpatient Admissions Per 1,000	38	37	1.6%	44	-14.9%
Inpatient Days per 1,000	171	180	-4.7%	225	-23.9%
Average Inpatient Day Cost	\$8,350	\$8,482	-1.6%	\$6,717	24.3%
Average Cost per Admission	\$38,001	\$41,174	-7.7%	\$34,185	11.2%
Readmission within 30 days per 1000	43	45	-3.1%	N/A	N/A
ER Visits per 1,000	190	177	7.1%	193	-2.0%
Rx Scripts per 1,000	9,599	10,456	-8.2%	14,133	-32.1%

### 4. Major Conditions—Prevalence and Cost (with Conditions)

Chronic Condition <sup>4</sup>	Current Period							% Change	
	Members	% of Total	Norm <sup>2</sup>	Medical Claims	% of Total	PMPY	PMPY Comparison <sup>5</sup>	Prevalence	PMPY
1. Diabetes	1,781	8.8%	7.3%	\$24,214,153	19.4%	\$13,596	221%	1.1%	18.6%
2. CAD	339	1.7%	2.5%	\$11,001,981	8.8%	\$32,454	528%	0.0%	-4.3%
3. Asthma	1,752	8.6%	8.1%	\$15,708,558	12.6%	\$8,966	146%	1.1%	8.5%
4. COPD	99	0.5%	0.6%	\$2,760,556	2.2%	\$27,884	454%	0.1%	-24.7%
5. Hypertension	3,828	18.9%	21.1%	\$48,401,348	38.9%	\$12,644	206%	0.7%	16.3%
6. Mental Health	7,344	36.2%	34.8%	\$59,145,282	47.5%	\$8,054	131%	1.7%	8.9%
7. SUD <sup>6</sup>	728	3.6%	2.9%	\$9,653,842	7.8%	\$13,261	216%	0.2%	11.0%
8. CHF	62	0.3%	0.4%	\$3,554,425	2.9%	\$57,329	934%	0.0%	-19.2%
<b>Totals (unique)</b>	<b>10,410</b>	<b>51.3%</b>		<b>\$87,330,347</b>	<b>70.1%</b>	<b>\$8,389</b>	<b>137%</b>	<b>2.2%</b>	<b>9.6%</b>

<sup>1</sup> "All Others" includes Ancillary type services such as Home, Ambulance, and DME.

<sup>2</sup> SHAPE database, public sector norms, based upon 2021 experience.

<sup>3</sup> Based on average medical membership.

<sup>4</sup> Members with co-morbidities and their corresponding claims are combined in each applicable category.

<sup>5</sup> Reflects the ratio of PMPY costs of members with the chronic condition to the total enrolled population.

<sup>6</sup> Substance Use Disorder (SUD) excludes tobacco use disorder.

### 5. High Risk High Cost Analysis (High Cost by Condition)

Chronic Condition For High Cost Claimants <sup>1</sup>	Current Period			Prior Period			% Change	
	Members	% Within Condition	PMPY	Members	% Within Condition	PMPY	Prev	PMPY
1. Diabetes	197	11.1%	\$88,133	144	9.1%	\$80,685	1.9%	9.2%
2. CAD	79	23.3%	\$117,768	76	21.9%	\$133,320	1.4%	-11.7%
3. Asthma	139	7.9%	\$63,236	117	7.6%	\$60,916	0.4%	3.8%
4. COPD	16	16.2%	\$142,710	21	25.9%	\$127,259	-9.8%	12.1%
5. Hypertension	369	9.6%	\$91,913	329	8.8%	\$81,988	0.8%	12.1%
6. CHF	20	32.3%	\$160,869	27	44.3%	\$150,815	-12.0%	6.7%
7. Breast Cancer	37	26.1%	\$93,389	36	25.9%	\$95,018	0.2%	-1.7%
8. Colon Cancer	12	37.5%	\$170,904	11	39.3%	\$199,991	-1.8%	-14.5%
9. Prostate Cancer	7	15.9%	\$64,990	12	23.5%	\$85,065	-7.6%	-23.6%
<b>Totals (unique)</b>	<b>510</b>		<b>\$85,036</b>	<b>456</b>		<b>\$80,676</b>	<b>0.4%</b>	<b>5.4%</b>

### 6. Clinical Quality Performance

Chronic Conditions	Clinical Quality Metrics	Population	Current Period	Prior Period	SHAPE Public Sector <sup>2</sup>
Diabetes	At least 1 hemoglobin A1C tests in last 12 months	1,781	81.0%	80.0%	79.1%
	Annual screening for diabetic nephropathy	1,781	55.2%	56.1%	62.7%
	Annual screening for diabetic retinopathy	1,781	17.6%	19.3%	35.2%
CAD	Patients currently taking an ACE-Inhibitor or ARB Drug	339	41.0%	42.9%	39.6%
	Patients currently taking a statin	339	59.6%	62.5%	68.9%
Hyperlipidemia	Total cholesterol testing in last 12 months	4,370	68.4%	54.7%	76.0%
COPD	Spirometry testing in last 12 months	99	18.2%	17.7%	28.2%
Asthma	Patients with inhaled corticosteroids or leukotriene inhibitors in the last 12 months	1,752	72.4%	82.8%	76.7%
Preventive Screening	Cervical cancer	9,434	22.7%	24.0%	38.0%
	Breast cancer	5,938	39.0%	39.6%	49.0%
	Colorectal cancer	6,390	36.1%	33.5%	38.1%
	Prostate cancer	2,751	36.6%	35.6%	48.2%

### 7. Summary of Prescription Drug Expenses

Category	Non-Specialty		Specialty		Total		
	Current Period	Change	Current Period	Change	Current Period	Prior Period	Change
Total Cost	\$18,200,359	14%	\$16,598,292	27.9%	\$34,798,651	\$28,934,945	20.3%
% of Total Costs	52.3%	-5.1%	47.7%	6.3%			
Total Scripts	190,915	-10.1%	3,712	27.8%	194,627	215,156	-9.5%
% of Total Scripts	98.1%	-0.6%	1.9%	41.3%			
Avg Cost PMPM	\$74.80	15.8%	\$68.22	29.8%	\$143.02	\$117.19	22.0%
Avg Cost Per Rx	\$95.33	26.8%	\$4,472	0.0%	\$178.80	\$134.48	33.0%
Number of Scripts PMPM	0.78	-8.7%	0.02	29.7%	0.80	0.87	-8.2%
Generic Dispensing Rate	83.5%	-2.0%	36.6%	-20.3%	82.6%	84.6%	-2.4%
Member Cost %	7.9%	-19.6%	24.4%	16.4%	15.8%	14.8%	6.5%

### 8. Prescription Drug Cost Management Analysis


Top 10 Indications	Prior Rank	Current Period				Prior Period			
		Rxs	Total Cost	Generic Fill Rate	PMPM	Rxs	Total Cost	Generic Fill Rate	PMPM
Diabetes	1	13,932	\$7,495,038	46.5%	\$30.80	14,981	\$6,385,856	54.8%	\$25.86
Autoimmune Disease	2	1,489	\$6,975,993	20.2%	\$28.67	1,011	\$6,046,779	33.5%	\$24.49
Oncology	3	1,077	\$2,793,466	73.8%	\$11.48	1,149	\$2,480,645	82.8%	\$10.05
Psoriasis	4	215	\$2,157,711	15.3%	\$8.87	129	\$1,277,146	32.6%	\$5.17
Rare Disorders	12	206	\$1,811,024	55.3%	\$7.44	138	\$459,161	81.2%	\$1.86
Asthma/COPD	5	8,840	\$1,219,148	77.6%	\$5.01	9,228	\$1,271,618	78.2%	\$5.15
Multiple Sclerosis/Neuromuscular Disorders	6	190	\$1,193,017	32.1%	\$4.90	131	\$1,124,869	22.9%	\$4.56
Vaccines/Immunizing Agents	7	9,341	\$937,653	0.0%	\$3.85	13,597	\$1,029,451	0.0%	\$4.17
Viral Infections/HIV AIDS	8	310	\$937,171	23.2%	\$3.85	362	\$977,127	25.1%	\$3.96
Diabetic Supplies/Monitoring	10	2,797	\$900,729	0.0%	\$3.70	2,405	\$612,537	0.0%	\$2.48
<b>Total Top 10:</b>		<b>38,397</b>	<b>\$26,420,951</b>	<b>38.3%</b>	<b>\$108.59</b>	<b>43,131</b>	<b>\$21,665,188</b>	<b>39.4%</b>	<b>\$87.74</b>

<sup>1</sup> High Cost Claimants are above \$25,000 (does not include Rx claims).

<sup>2</sup> Source: SHAPE database, public sector norms, based upon 2021 experience.



### 1. Principal Financial Trends—Claims Cost



### 2. Claims Summary

Place of Service	Current Period			Prior Period			% Change in PMPM
	Total Paid Amount	Total Paid PMPM	% of Total	Total Paid Amount	Total Paid PMPM	% of Total	
Outpatient Hospital	\$63,302,143	\$217.59	28.4%	\$57,703,533	\$196.40	27.1%	10.8%
Inpatient Hospital	\$33,151,819	\$113.95	14.9%	\$38,636,464	\$131.50	18.2%	-13.3%
Professional	\$30,656,275	\$105.37	13.7%	\$32,833,525	\$111.75	15.4%	-5.7%
Emergency Room	\$18,098,365	\$62.21	8.1%	\$16,294,154	\$55.46	7.7%	12.2%
Urgent Care	\$171,041	\$0.59	0.1%	\$171,797	\$0.58	0.1%	0.5%
Drugs (Medical)	\$19,741,956	\$67.86	8.8%	\$16,715,469	\$56.89	7.9%	19.3%
All Others <sup>1</sup>	\$3,845,800	\$13.22	1.7%	\$4,039,529	\$13.75	1.9%	-3.9%
<b>Total Medical</b>	<b>\$168,967,400</b>	<b>\$580.79</b>	<b>75.7%</b>	<b>\$166,394,473</b>	<b>\$566.35</b>	<b>78.3%</b>	<b>2.6%</b>
<b>Total Rx</b>	<b>\$54,154,987</b>	<b>\$186.15</b>	<b>24.3%</b>	<b>\$46,194,655</b>	<b>\$157.23</b>	<b>21.7%</b>	<b>18.4%</b>
<b>Total Paid</b>	<b>\$223,122,387</b>	<b>\$766.94</b>	<b>100.0%</b>	<b>\$212,589,127</b>	<b>\$723.57</b>	<b>100.0%</b>	<b>6.0%</b>
<b>Member Paid</b>	<b>\$27,712,200</b>	<b>\$95.25</b>	<b>12.4%</b>	<b>\$25,389,490</b>	<b>\$86.42</b>	<b>11.9%</b>	<b>10.2%</b>
<b>Plan Paid</b>	<b>\$195,410,187</b>	<b>\$671.68</b>	<b>87.6%</b>	<b>\$187,199,637</b>	<b>\$637.16</b>	<b>88.1%</b>	<b>5.4%</b>

### 3. Key Healthcare Performance Metrics

Category	Current Period	Prior Period	Change	Norm <sup>2</sup>	Comparison to Norm
Avg Membership Per Month <sup>3</sup>	24,244	24,484	-1.0%	N/A	N/A
Office Visits per 1,000	5,280	4,872	8.4%	4,261	23.9%
Preventive Visits per 1,000	763	725	5.2%	N/A	N/A
Inpatient Admissions Per 1,000	46	47	-2.2%	46	1.4%
Inpatient Days per 1,000	196	245	-20.2%	238	-17.8%
Average Inpatient Day Cost	\$6,787	\$6,251	8.6%	\$6,631	2.4%
Average Cost per Admission	\$28,676	\$32,355	-11.4%	\$34,537	-17.0%
Readmission within 30 days per 1000	90	71	27.2%	N/A	N/A
ER Visits per 1,000	222	211	5.5%	196	13.5%
Rx Scripts per 1,000	12,441	13,668	-9.0%	14,385	-13.5%

### 4. Major Conditions—Prevalence and Cost (with Conditions)

Chronic Condition <sup>4</sup>	Current Period							% Change	
	Members	% of Total	Norm <sup>2</sup>	Medical Claims	% of Total	PMPY	PMPY Comparison <sup>5</sup>	Prevalence	PMPY
1. Diabetes	2,601	10.7%	7.7%	\$35,551,961	21.0%	\$13,669	196%	1.6%	2.0%
2. CAD	718	3.0%	2.9%	\$22,510,523	13.3%	\$31,352	450%	0.0%	2.0%
3. Asthma	2,623	10.8%	8.2%	\$24,701,870	14.6%	\$9,417	135%	1.5%	-3.2%
4. COPD	183	0.8%	0.7%	\$5,686,853	3.4%	\$31,076	446%	0.1%	1.2%
5. Hypertension	5,939	24.5%	22.5%	\$77,218,766	45.7%	\$13,002	187%	0.6%	1.2%
6. Mental Health	2,399	9.9%	34.6%	\$26,510,498	15.7%	\$11,051	159%	0.0%	25.2%
7. SUD <sup>6</sup>	127	0.5%	3.0%	\$1,855,867	1.1%	\$14,613	210%	0.0%	78.0%
8. CHF	105	0.4%	0.5%	\$4,806,004	2.8%	\$45,771	657%	0.0%	-23.5%
<b>Totals (unique)</b>	<b>9,549</b>	<b>39.4%</b>		<b>\$104,896,508</b>	<b>62.1%</b>	<b>\$10,985</b>	<b>158%</b>	<b>1.7%</b>	<b>3.9%</b>

<sup>1</sup> "All Others" includes Ancillary type services such as Home, Ambulance, and DME.  
<sup>2</sup> SHAPE database, public sector norms, based upon 2021 experience.  
<sup>3</sup> Based on average medical membership.  
<sup>4</sup> Members with co-morbidities and their corresponding claims are combined in each applicable category.  
<sup>5</sup> Reflects the ratio of PMPY costs of members with the chronic condition to the total enrolled population.  
<sup>6</sup> Substance Use Disorder (SUD) excludes tobacco use disorder.

### 5. High Risk High Cost Analysis (High Cost by Condition)

Chronic Condition for High Cost Claimants <sup>1</sup>	Current Period			Prior Period			% Change	
	Members	% Within Condition	PMPY	Members	% Within Condition	PMPY	Prev	PMPY
1. Diabetes	308	11.8%	\$80,343	253	11.3%	\$81,407	0.5%	-1.3%
2. CAD	200	27.9%	\$94,807	198	26.9%	\$96,083	1.0%	-1.3%
3. Asthma	209	8.0%	\$65,075	175	7.6%	\$73,953	0.3%	-12.0%
4. COPD	45	24.6%	\$104,389	39	24.5%	\$106,551	0.1%	-2.0%
5. Hypertension	670	11.3%	\$78,905	629	10.8%	\$81,818	0.5%	-3.6%
6. CHF	43	41.0%	\$101,917	44	40.4%	\$136,281	0.6%	-25.2%
7. Breast Cancer	61	26.5%	\$130,049	58	26.5%	\$97,747	0.0%	33.0%
8. Colon Cancer	21	35.6%	\$142,524	17	35.4%	\$128,668	0.2%	10.8%
9. Prostate Cancer	22	28.6%	\$94,920	20	24.7%	\$75,937	3.9%	25.0%
<b>Totals (unique)</b>	<b>842</b>		<b>\$81,091</b>	<b>777</b>		<b>\$80,468</b>	<b>0.4%</b>	<b>0.8%</b>

### 6. Clinical Quality Performance

Chronic Conditions	Clinical Quality Metrics	Population	Current Period	Prior Period	SHAPE Public Sector <sup>2</sup>
Diabetes	At least 1 hemoglobin A1C tests in last 12 months	2,601	81.0%	82.0%	79.6%
	Annual screening for diabetic nephropathy	2,601	54.3%	58.5%	63.2%
	Annual screening for diabetic retinopathy	2,601	18.2%	19.4%	36.1%
CAD	Patients currently taking an ACE-Inhibitor or ARB Drug	718	45.3%	48.3%	40.3%
	Patients currently taking a statin	718	63.0%	63.2%	70.0%
Hyperlipidemia	Total cholesterol testing in last 12 months	6,492	71.4%	70.5%	76.3%
COPD	Spirometry testing in last 12 months	183	24.6%	15.2%	28.4%
Asthma	Patients with inhaled corticosteroids or leukotriene inhibitors in the last 12 months	2,623	72.3%	82.1%	76.9%
Preventive Screening	Cervical cancer	11,026	24.7%	25.4%	37.7%
	Breast cancer	7,038	42.8%	40.8%	49.6%
	Colorectal cancer	8,412	34.7%	33.4%	38.0%
	Prostate cancer	3,690	44.4%	43.2%	48.6%

### 7. Summary of Prescription Drug Expenses


Category	Non-Specialty		Specialty		Total		
	Current Period	Change	Current Period	Change	Current Period	Prior Period	Change
Total Cost	\$29,976,139	17%	\$24,178,848	17.4%	\$54,154,987	\$46,194,655	17.2%
% of Total Costs	55.4%	-0.1%	44.6%	0.1%			
Total Scripts	295,417	-10.3%	6,200	18.0%	301,617	334,642	-9.9%
% of Total Scripts	97.9%	-0.5%	2.1%	30.9%			
Avg Cost PMPM	\$103.04	18.3%	\$83.11	18.5%	\$186.15	\$157.23	18.4%
Avg Cost Per Rx	\$101.47	30.6%	\$3,900	-0.5%	\$179.55	\$138.04	30.1%
Number of Scripts PMPM	1.02	-9.4%	0.02	19.1%	1.04	1.14	-9.0%
Generic Dispensing Rate	83.9%	-2.3%	44.1%	-19.1%	83.1%	85.4%	-2.7%
Member Cost %	8.0%	-18.8%	24.8%	22.1%	15.5%	14.5%	6.8%

### 8. Prescription Drug Cost Management Analysis

Top 10 Indications	Prior Rank	Current Period				Prior Period			
		Rxs	Total Cost	Generic Fill Rate	PMPM	Rxs	Total Cost	Generic Fill Rate	PMPM
Diabetes	1	22,297	\$12,740,294	43.1%	\$43.79	23,975	\$10,527,829	50.5%	\$35.83
Autoimmune Disease	2	2,026	\$9,148,437	25.9%	\$31.45	1,503	\$8,219,446	36.8%	\$27.98
Oncology	3	1,849	\$5,162,321	78.0%	\$17.74	1,942	\$3,826,818	86.3%	\$13.03
Psoriasis	4	456	\$3,837,411	7.0%	\$13.19	334	\$2,859,570	23.1%	\$9.73
Asthma/COPD	5	14,018	\$2,111,318	77.6%	\$7.26	14,839	\$2,036,683	78.5%	\$6.93
Multiple Sclerosis	7	181	\$1,470,575	43.1%	\$5.05	160	\$1,254,863	27.5%	\$4.27
Viral Infections/HIV	6	501	\$1,366,550	27.5%	\$4.70	514	\$1,280,248	30.9%	\$4.36
Diabetic Supplies/Monitoring	12	4,179	\$1,304,363	0.0%	\$4.48	3,362	\$801,776	0.0%	\$2.73
Skin Disorders	8	5,346	\$1,253,403	93.0%	\$4.31	4,806	\$1,074,137	93.9%	\$3.66
Blood Disorders	9	2,673	\$1,179,329	49.3%	\$4.05	3,167	\$1,042,502	55.0%	\$3.55
<b>Total Top 10:</b>		<b>53,526</b>	<b>\$39,574,002</b>	<b>54.2%</b>	<b>\$136.03</b>	<b>54,602</b>	<b>\$32,923,873</b>	<b>59.6%</b>	<b>\$112.06</b>

<sup>1</sup> High Cost Claimants are above \$25,000 (does not include Rx claims).  
<sup>2</sup> Source: SHAPE database, public sector norms, based upon 2021 experience.

## 1. Principal Financial Trends—Claims Cost



## 2. Claims Summary

Place of Service	Current Period			Prior Period			% Change in PMPM
	Total Paid Amount	Total Paid PMPM	% of Total	Total Paid Amount	Total Paid PMPM	% of Total	
Outpatient Hospital	\$986,879	\$198.73	32.6%	\$421,838	\$144.56	31.2%	37.5%
Inpatient Hospital	\$793,836	\$159.85	26.2%	\$127,508	\$43.70	9.4%	265.8%
Professional	\$423,177	\$85.21	14.0%	\$240,177	\$82.31	17.8%	3.5%
Emergency Room	\$213,880	\$43.07	7.1%	\$139,632	\$47.85	10.3%	-10.0%
Urgent Care	\$26,040	\$5.24	0.9%	\$15,603	\$5.35	1.2%	-1.9%
Drugs (Medical)	\$9,509	\$1.91	0.3%	\$9,366	\$3.21	0.7%	-40.3%
All Others <sup>1</sup>	\$23,236	\$4.68	0.8%	\$12,778	\$4.38	0.9%	6.8%
<b>Total Medical</b>	<b>\$2,476,557</b>	<b>\$498.70</b>	<b>81.9%</b>	<b>\$966,902</b>	<b>\$331.36</b>	<b>71.5%</b>	<b>50.5%</b>
<b>Total Rx</b>	<b>\$548,171</b>	<b>\$110.38</b>	<b>18.1%</b>	<b>\$384,464</b>	<b>\$131.76</b>	<b>28.5%</b>	<b>-16.2%</b>
<b>Total Paid</b>	<b>\$3,024,728</b>	<b>\$609.09</b>	<b>100.0%</b>	<b>\$1,351,366</b>	<b>\$463.11</b>	<b>100.0%</b>	<b>31.5%</b>
<b>Member Paid</b>	<b>\$436,333</b>	<b>\$87.86</b>	<b>14.4%</b>	<b>\$226,786</b>	<b>\$77.72</b>	<b>16.8%</b>	<b>13.1%</b>
<b>Plan Paid</b>	<b>\$2,588,395</b>	<b>\$521.22</b>	<b>85.6%</b>	<b>\$1,124,581</b>	<b>\$385.39</b>	<b>83.2%</b>	<b>35.2%</b>

## 3. Key Healthcare Performance Metrics

Category	Current Period	Prior Period	Change	Norm <sup>2</sup>	Comparison to Norm
Avg Membership Per Month <sup>3</sup>	414	243	70.2%	N/A	N/A
Office Visits per 1,000	3,530	3,430	2.9%	3,952	-10.7%
Preventive Office Visits per 1,000	2	625	-99.6%	N/A	N/A
Inpatient Admissions Per 1,000	46	21	123.3%	45	1.3%
Inpatient Days per 1,000	263	90	191.1%	216	22.1%
Average Inpatient Day Cost	\$7,545	\$5,251	43.7%	\$7,010	7.6%
Average Cost per Admission	\$43,285	\$23,104	87.3%	\$33,354	29.8%
Readmission within 30 days per 1000	0	0	#DIV/0!	N/A	N/A
ER Visits per 1,000	244	160	52.2%	189	29.0%
Rx Scripts per 1,000	9,526	9,837	-3.2%	13,079	-27.2%

<sup>1</sup> "All Others" includes Ancillary type services such as Home, Ambulance, and DME.  
<sup>2</sup> SHAPE data warehouse, 2021 Public sector experience.  
<sup>3</sup> Based on average medical membership.  
<sup>4</sup> Members with co-morbidities and their corresponding claims are combined in each applicable category.  
<sup>5</sup> Reflects the ratio of PMPY costs of members with the chronic condition to the total enrolled population.  
<sup>6</sup> Substance Use Disorder (SUD) excludes tobacco use disorder.

## 4. Major Conditions—Prevalence and Cost (with Conditions)

Chronic Condition <sup>4</sup>	Current Period							% Change	
	Members	% of Total	Norm <sup>2</sup>	Medical Claims	% of Total	PMPY	PMPY Comparison <sup>5</sup>	Prevalence	PMPY
1. Diabetes	28	6.8%	6.3%	\$261,837	10.6%	\$9,351	156%	0.6%	-37.0%
2. CAD	<20	<Norm	2.0%	\$88,943	3.6%	>\$15K	>200%	0.4%	-79.4%
3. Asthma	25	6.0%	7.8%	\$237,506	9.6%	\$9,500	159%	2.8%	24.9%
4. COPD	0	0.0%	0.5%	\$0	0.0%	\$0	N/A	0.0%	0.0%
5. Hypertension	65	15.7%	18.2%	\$1,089,763	44.0%	\$16,766	280%	0.9%	53.4%
6. Mental Health	92	22.2%	33.8%	\$667,123	26.9%	\$7,251	121%	5.8%	140.0%
7. SUD <sup>6</sup>	<20	<Norm	2.7%	\$493,133	19.9%	>\$50K	>1000%	0.4%	30685%
8. CHF	<20	<Norm	0.3%	\$51,317	2.1%	>\$50K	>500%	-0.2%	-66.2%
<b>Totals (unique)</b>	<b>163</b>	<b>39.4%</b>		<b>\$1,677,312</b>	<b>67.7%</b>	<b>\$10,290</b>	<b>172%</b>	<b>9.0%</b>	<b>50.6%</b>

\* CIGNA experience started January 1, 2021 ;  
 Prior period data is immature.

**5. High Risk High Cost Analysis (High Cost by Condition)**

**N/A**  
 Group too small

**6. Clinical Quality Performance**

Chronic Conditions	Clinical Quality Metrics	Population	Current Period	Prior Period	SHAPE Public Sector <sup>2</sup>
Diabetes	At least 1 hemoglobin A1C tests in last 12 months	28	53.6%	53.3%	78.3%
	Annual screening for diabetic nephropathy	28	46.4%	13.3%	62.0%
	Annual screening for diabetic retinopathy	28	10.7%	6.7%	34.3%
CAD	Patients currently taking an ACE-Inhibitor or ARB Drug	<20	>Norm	>Norm	39.5%
	Patients currently taking a statin	<20	<Norm	>Norm	68.6%
Hyperlipidemia	Total cholesterol testing in last 12 months	67	53.7%	33.3%	75.7%
COPD	Spirometry testing in last 12 months	0	0.0%	0.0%	27.8%
Asthma	Patients with inhaled corticosteroids or leukotriene inhibitors in the last 12 months	25	92.0%	100.0%	76.5%
Preventive Screening	Cervical cancer	218	16.5%	5.1%	38.4%
	Breast cancer	125	19.2%	11.5%	48.4%
	Colorectal cancer	<20	<Norm	<Norm	37.6%
	Prostate cancer	56	19.6%	6.3%	48.2%

**7. Summary of Prescription Drug Expenses**

Category	Non-Specialty		Specialty		Total		
	Current Period	Change	Current Period	Change	Current Period	Prior Period	Change
Total Cost	\$403,147	108%	\$145,024	-23.8%	\$548,171	\$384,464	42.6%
% of Total Costs	73.5%	45.6%	26.5%	-46.5%			
Total Scripts	3,892	64.6%	50	78.6%	3,942	2,392	64.8%
% of Total Scripts	98.7%	-0.1%	1.3%	8.4%			
Avg Cost PMPM	\$81.18	21.9%	\$29.20	-55.2%	\$110.38	\$131.76	-16.2%
Avg Cost Per Rx	\$103.58	26.1%	\$2,900	-57.3%	\$139.06	\$160.73	-13.5%
Number of Scripts PMPM	0.78	-3.3%	0.01	4.9%	0.79	0.82	-3.2%
Generic Dispensing Rate	82.0%	-2.9%	58.0%	24.9%	81.7%	84.0%	-2.8%
Member Cost %	6.7%	-39.7%	26.2%	30.1%	11.9%	15.6%	-23.8%

**8. Prescription Drug Cost Management Analysis**

Top 10 Indications	Prior Rank	Current Period				Prior Period			
		Rxs	Total Cost	Generic Fill Rate	PMPM	Rxs	Total Cost	Generic Fill Rate	PMPM
Diabetes	2	231	\$152,002	26.8%	\$30.61	156	\$86,290	49.4%	\$29.57
Autoimmune Disease	1	<50	\$145,005	34.4%	\$29.20	<50	\$144,629	48.0%	\$49.56
Blood Disorders	11	<50	\$25,721	7.1%	\$5.18	<50	\$5,642	0.0%	\$1.93
Diabetic Supplies/Monitoring	8	75	\$25,323	0.0%	\$5.10	<50	\$6,778	0.0%	\$2.32
Asthma/COPD	9	202	\$21,257	79.2%	\$4.28	86	\$6,746	86.0%	\$2.31
Digestive Aids	20	<50	\$16,680	0.0%	\$3.36	<50	\$2,113	0.0%	\$0.72
Anti-Infectives	12	351	\$14,185	100.0%	\$2.86	233	\$4,852	100.0%	\$1.66
Mental Health	47	<50	\$11,937	87.0%	\$2.40	<50	\$88	100.0%	\$0.03
ADHD/Narcolepsy	22	56	\$10,250	66.1%	\$2.06	<50	\$1,464	100.0%	\$0.50
Vaccines/Immunizing Agents	5	161	\$9,813	0.0%	\$1.98	157	\$8,005	0.0%	\$2.74
<b>Total Top 10:</b>		<b>1,167</b>	<b>\$432,174</b>	<b>55.1%</b>	<b>\$87.03</b>	<b>754</b>	<b>\$266,606</b>	<b>59.2%</b>	<b>\$91.37</b>

<sup>1</sup> High Cost Claimants are above \$25,000 (does not include Rx claims).  
<sup>2</sup> Source: SHAPE data warehouse, 2021 Public sector experience.

\* CIGNA experience started January 1, 2021;  
 Prior period data is immature.

## Dashboard Overview

The purpose of this monthly dashboard is to:

- Highlight key metrics to monitor progress against strategic opportunities.
- Provide a mechanism to track:
  - **Claims and trends:** determine cost trend drivers plus analyze data on effective alternatives to manage those trends
  - **Utilization metrics vs. benchmark:** compare the plan's utilization to benchmarks and desired targets.
  - **Population health status:** assess disease burden and recommend solutions to lessen future trend increases; Uncover opportunities for the plan to better control plan cost and improve the health of the covered population.

## Methodology/Definitions

- Generally, financial metrics are reported on a total cost/allowed basis (i.e., total cost includes plan paid and member cost sharing). This allows for tracking of population health status for improvement over time.
- Claims are reported on an incurred basis for the periods July 1, 2022 – June 30, 2023 (current period) and July 1, 2021 – June 30, 2022 (prior period) with three months' runout for each period.

## Norms/Benchmarks

- Where benchmarks are shown, we are using Segal's SHAPE data warehouse, public sector data from 2019; adjusted for group demographics.

## 1. Principal Financial Trends

**Objective:** Provide a visual representation of how claims are trending over the short term.

- Seasonality in claims paid is expected with the highest monthly claims generally occurring in winter; 6-month rolling average is used to smooth the effect of seasonality.
- Monthly claims can fluctuate at the beginning and end of a plan year as members determine if their contribution to the out-of-pocket maximum warrants getting medical treatment in the current year or waiting until the next plan year.

## 2. Claims Summary

**Objective:** Provide a comparative overview of claims based on treatment setting. Also provides a summary of plan paid, member paid and total plan allowed costs.

- Place of Service can be helpful when investigating changes in utilization patterns or when trying to understand the impact of plan design changes.

## 3. Key Healthcare Performance Metrics

**Objective:** Provide some key comparative utilization metrics to track sources of claims increases.

- This table allows the plan to understand whether changes in cost are driven by price or change in utilization.

## 4. Major Chronic Conditions—Prevalence and Cost

**Objective:** Provide metrics to monitor the cost and utilization of chronic conditions.



## 5. High Risk High Cost Analysis High Cost by Condition

**Objective:** Provide key metrics to monitor cost and utilization of high risk and high cost chronic conditions. Target high risk groups for medical management interventions.

## 6. Clinical Quality Performance

**Objective:** Provide clinical metrics related to preventive screening, treatment compliance rates, and quality of care performance measures. This report enables the plan to determine the degree to which participants are receiving adequate care from an NCQA / HEDIS perspective.

## 7. Summary of Prescription Drug Expenses

**Objective:** Provide metrics to evaluate year-over-year growth in pharmacy spend, cost and utilization.


- This report enables the plan to determine the effectiveness of the current drug benefit design in terms of cost and utilization, and may help identify improvement opportunities.

## 8. Prescription Drug Cost Management Analysis

**Objective:** Provide a list of the top 10 drug indications that are driving pharmacy claim expenses.

- It enables the plan to determine what categories of drugs are driving utilization and cost over time. This may help identify those areas where opportunities exist for improved utilization management or plan design.

- Data presented has been “de-identified”, which means it does not contain names or SSNs, etc.
- Specific medical conditions are identified.
- If the plan administrator knows the identity of individuals with a specific condition, that information is considered PHI.
- PHI is subject to the HIPAA Privacy Rule’s protections, which means it must be kept confidential and cannot be used for any reason other than health plan administration (e.g., using it for employment purposes, or by other benefit plans, is prohibited).





**New Mexico  
Public Schools  
Insurance  
Authority**

## December 2023 Benefits Statistics

July 2023-September 2023

1<sup>st</sup>Quarter

### 251 Total Inquiries

188 Phone Calls  
60 Website Feedback  
3 Emails

### Days Resolved

1 Day= 206  
2 Days= 27  
3 Days= 13  
4 Days= 5

### Carriers 46

### General 205

Blue Cross Blue Shield	2		Erisa Administrative Services	72
Presbyterian	4		Employer	68
Cigna	0		NMPSIA	33
CVS	11		NMRHCA	18
United Concordia	1		Risk	9
Delta Dental	1		CCMSI	3
Davis Vision	0		Albuquerque Public Schools	1
The Standard	7		Medicare	1
ID cards	20			



# New Mexico Public Schools Insurance Authority

Administrative Office: Erisa Administrative Services, Inc.

P. O. Box 9054; Santa Fe, NM 87504

Phone: (505) 988-4974 or (800) 233-3164 Fax: (505) 988-8943



12/01/2023

## OPEN ENROLLMENT COUNTS FOR 2024

### Medical

Carrier	Employee Count	Employee and Dependents Count
BCBS HIGH	305	655
BCBS LOW	63	101
BCBS EPO	16	26
PRES HIGH	217	377
PRES LOW	130	220
CIGA HIGH	10	20
CIGA LOW	7	13
TOTAL	748	1,412

### Dental

Carrier	Employee Count	Employee and Dependents Count
UCD HIGH	165	360
UCD LOW	11	17
DLTA HIGH	543	1,115
DLTA LOW	65	113
TOTAL	784	1,605

### Vision

Employee Count	647	Employee and Dependents Count	1,309
----------------	-----	-------------------------------	-------



# New Mexico Public Schools Insurance Authority

Administrative Office: Erisa Administrative Services, Inc.  
P. O. Box 9054; Santa Fe, NM 87504



Phone: (505) 988-4974 or (800) 233-3164 Fax: (505) 988-8943

12/01/2023

## SWITCH ENROLLMENT EMPLOYEE COUNTS FOR 01/01/2024

### Medical

UW	PLAN	LOSS	GAIN	NET
BCBS	EPO	12	6	-6
BCBS	H	75	132	57
BCBS	L	73	64	-9
CIGA	H	8	11	3
CIGA	L	8	9	1
PRES	H	102	92	-10
PRES	L	104	68	-36

Medical Total Number of Switches: 382

### Dental

UW	PLAN	LOSS	GAIN	NET
DLTA	B	43	15	-28
DLTA	C	42	212	170
UCD	B	52	10	-42
UCD	C	157	57	-100

Dental Total Number of Switches: 294



# New Mexico Public Schools Insurance Authority

Administrative Office: Erisa Administrative Services, Inc.  
P. O. Box 9054; Santa Fe, NM 87504



Phone: (505) 988-4974 or (800) 233-3164 Fax: (505) 988-8943

12/01/2023

## SWITCH ENROLLMENT FROM 2024

### Medical

Old UW	Old Plan	New UW	New Plan	Count
BCBS	EPO	BCBS	H	6
BCBS	EPO	CIGA	L	1
BCBS	EPO	PRES	H	4
BCBS	EPO	PRES	L	1
BCBS	H	BCBS	EPO	1
BCBS	H	BCBS	L	38
BCBS	H	CIGA	H	1
BCBS	H	CIGA	L	1
BCBS	H	PRES	H	21
BCBS	H	PRES	L	13
BCBS	L	BCBS	H	58
BCBS	L	CIGA	L	2
BCBS	L	PRES	H	3
BCBS	L	PRES	L	10
CIGA	H	BCBS	H	4
CIGA	H	CIGA	L	2
CIGA	H	PRES	H	2
CIGA	L	BCBS	L	1
CIGA	L	CIGA	H	5
CIGA	L	PRES	L	2
PRES	H	BCBS	EPO	4



# New Mexico Public Schools Insurance Authority

Administrative Office: Erisa Administrative Services, Inc.  
 P. O. Box 9054; Santa Fe, NM 87504



Phone: (505) 988-4974 or (800) 233-3164 Fax: (505) 988-8943

PRES	H	BCBS	H	48
PRES	H	BCBS	L	3
PRES	H	CIGA	H	4
PRES	H	CIGA	L	1
PRES	H	PRES	L	42
PRES	L	BCBS	EPO	1
PRES	L	BCBS	H	16
PRES	L	BCBS	L	22
PRES	L	CIGA	H	1

## Dental


Old UW	Old Plan	New UW	New Plan	Count
DLTA	B	DLTA	C	40
DLTA	B	UCD	C	3
DLTA	C	DLTA	B	11
DLTA	C	UCD	B	1
DLTA	C	UCD	C	30
UCD	B	DLTA	B	2
UCD	B	DLTA	C	26
UCD	B	UCD	C	24
UCD	C	DLTA	B	2
UCD	C	DLTA	C	146
UCD	C	UCD	B	9

# NEW MEXICO SAFE SCHOOL SUMMIT

**TOGETHER, FOR OUR FUTURE**

First Annual  
New Mexico Safe School Summit  
November 13th, 14th & 15th  
2023

Santa Ana Star Casino and Hotel  
Bernalillo, New Mexico  
Hosted by:



New Mexico  
Public Schools  
Insurance  
Authority



Carpenter  
Consulting, LLC



Office of the Governor

**MICHELLE LUJAN GRISHAM**



**LOS LUNAS SCHOOLS®**





**NMPSIA BOARD REPORT SUMMARY - LIABILITY AND PROPERTY**

10-31-2023

ALL YEARS TOTAL OPEN CLAIMS FOR LIABILITY AS OF OCTOBER 31, 2023							ALL YEARS TOTAL OPEN CLAIMS FOR PROPERTY AS OF OCTOBER 31, 2023						GRAND TOTALS	
SCHOOL DISTRICT	NUMBER OF OPEN CLAIMS	NUMBER OF NEW CLAIMS	NUMBER OF CLOSED CLAIMS	RESERVE	PAYMENT	TOTAL	NUMBER OF OPEN CLAIMS	NUMBER OF NEW CLAIMS	NUMBER OF CLOSED CLAIMS	RESERVE	PAYMENT	TOTAL	TOTAL	GRAND TOTAL
SUBTOTAL - DISTRICTS	380	48	41	\$24,079,617.15	\$10,991,842.69	\$35,071,459.84	131	29	13	\$69,031,628.25	\$21,231,284.77	\$90,262,913.02	511	\$125,334,372.86
SUBTOTAL - CHARTER SCHOOLS	24	1	0	\$588,046.75	\$37,252.60	\$625,299.35	5	1	2	\$11,986.52	\$90,656.25	\$102,642.77	29	\$727,942.12
GRAND TOTAL	404	49	41	\$24,667,663.90	\$11,029,095.29	\$35,696,759.19	136	30	15	\$69,043,614.77	\$21,321,941.02	\$90,365,555.79	540	\$126,062,314.98

CHANGE FROM PRIOR MONTH	CURRENT CHANGES LIABILITY CLAIMS FROM PRIOR MONTH						CURRENT CHANGES PROPERTY CLAIMS FROM PRIOR MONTH						CURRENT CHANGES	
SCHOOL DISTRICT	OPEN CLAIMS	NEW CLAIMS	CLOSED CLAIMS	RESERVE	PAYMENT	TOTAL	OPEN CLAIMS	NEW CLAIMS	CLOSED CLAIMS	RESERVE	PAYMENT	TOTAL	OPEN CLAIMS	GRAND TOTAL
SUBTOTAL - DISTRICTS	9	15	10	\$1,113,662.66	\$484,224.45	\$1,597,887.11	20	14	11	\$768,653.59	(\$3,433,042.40)	(\$2,664,388.81)	29	(\$1,066,501.70)
SUBTOTAL - CHARTER SCHOOLS	1	(1)	(2)	\$149,329.55	\$2,770.45	\$152,100.00	(1)	(1)	(1)	(\$35,516.24)	\$30.00	(\$35,486.24)	0	\$116,613.76
GRAND TOTAL	10	14	8	\$1,262,992.21	\$486,994.90	\$1,749,987.11	19	13	10	\$733,137.35	(\$3,433,012.40)	(\$2,699,875.05)	29	(\$949,887.94)

HISTORY	MONTH TOTAL						MONTH TOTAL CHANGES FROM PRIOR MONTH TOTAL					
Monthly Totals	Open Claims	New Claims	Closed Claims	RESERVE	PAYMENTS	TOTAL	Open Claims	New Claims	Closed Claims	RESERVE	PAYMENTS	TOTAL
October - 2023	540	79	56	\$93,711,278.67	\$32,351,036.31	\$126,062,314.98	29	27	18	\$1,996,129.56	(\$2,946,017.50)	(\$949,887.94)
September - 2023	511	52	38	\$91,715,149.11	\$35,297,053.81	\$127,012,202.92	19	(3)	(26)	(\$1,266,805.79)	\$2,767,421.22	\$1,500,615.43
August - 2023	492	55	64	\$92,981,954.90	\$32,529,632.59	\$125,511,587.49	(5)	(31)	(3)	\$4,695,525.49	(\$7,037,658.70)	(\$2,342,133.21)
July - 2023	497	86	67	\$88,286,429.41	\$39,567,291.29	\$127,853,720.70	24	38	20	\$3,192,782.91	\$1,079,304.89	\$4,272,087.80
June - 2023	473	48	47	\$85,093,646.50	\$38,487,986.40	\$123,581,632.90	9	(13)	(36)	\$28,611,890.88	(\$3,279,230.43)	\$25,332,660.45
May - 2023	464	61	83	\$56,481,755.62	\$41,767,216.83	\$98,248,972.45	(15)	7	24	(\$2,940,892.57)	\$2,132,509.33	(\$808,383.24)
April - 2023	479	54	59	\$59,422,648.19	\$39,634,707.50	\$99,057,355.69	1	(15)	(4)	(\$2,764,490.56)	\$4,999,879.61	\$2,235,389.05
March - 2023	478	69	63	\$62,187,138.75	\$34,634,827.89	\$96,821,966.64	11	18	24	\$1,287.92	\$1,139,897.50	\$1,141,185.42
February - 2023	467	51	39	\$62,185,850.83	\$33,494,930.39	\$95,680,781.22	19	(10)	(8)	\$571,024.43	\$1,187,977.05	\$1,759,001.48
January - 2023	448	61	47	\$61,614,826.40	\$32,306,953.34	\$93,921,779.74	18	29	0	\$361,499.20	(\$175,637.96)	\$185,861.24
December - 2022	430	32	47	\$61,253,327.20	\$32,482,591.30	\$93,735,918.50	(13)	(30)	(12)	(\$1,886,367.25)	(\$3,797,977.87)	(\$5,684,345.12)
November - 2022	443	62	59	\$63,139,694.45	\$36,280,569.17	\$99,420,263.62	13	(20)	(17)	\$2,289,852.48	(\$425,745.37)	\$1,864,107.11
October - 2022	430	82	76	\$60,849,841.97	\$36,706,314.54	\$97,556,156.51	8	39	31	\$437,166.04	(\$4,136,937.99)	(\$3,699,771.95)
September - 2022	422	43	45	\$60,412,675.93	\$40,843,252.53	\$101,255,928.46	5	(29)	(15)	\$1,683,415.42	\$1,226,358.10	\$2,909,773.52
August - 2022	417	72	60	\$58,729,260.51	\$39,616,894.43	\$98,346,154.94	15	54	31	\$970,635.92	\$2,352,124.71	\$3,322,760.63
July - 2022	402	18	29	\$57,758,624.59	\$37,264,769.72	\$95,023,394.31	(6)	(39)	(11)	\$20,243,939.17	\$4,938,782.62	\$25,182,721.79
June - 2022	408	57	40	\$37,514,685.42	\$32,325,987.10	\$69,840,672.52	27	2	(33)	(\$813,665.77)	\$1,639,986.34	\$826,320.57
May - 2022	381	55	73	\$38,328,351.19	\$30,686,000.76	\$69,014,351.95	(16)	11	40	(\$5,203,062.14)	\$3,030,181.71	(\$2,172,880.43)
April - 2022	397	44	33	\$43,531,413.33	\$27,655,819.05	\$71,187,232.38	21	(25)	(7)	\$342,327.71	\$1,366,532.28	\$1,708,859.99
March - 2022	376	69	40	\$43,189,085.62	\$26,289,286.77	\$69,478,372.39	34	22	6	\$1,481,802.34	\$1,290,433.83	\$2,772,236.17
February - 2022	342	47	34	\$41,707,283.28	\$24,998,852.94	\$66,706,136.22	15	8	0	\$2,051,510.59	(\$272,536.59)	\$1,778,974.00
January - 2022	327	39	34	\$39,655,772.69	\$25,271,389.53	\$64,927,162.22	7	4	(17)	(\$2,780,159.39)	(\$279,539.15)	(\$3,059,698.54)
December - 2021	320	35	51	\$42,435,932.08	\$25,550,928.68	\$67,986,860.76	(14)	(12)	13	\$733,971.22	(\$846,129.80)	(\$112,158.58)
November - 2021	334	47	38	\$41,701,960.86	\$26,397,058.48	\$68,099,019.34	16	13	(12)	\$428,298.90	(\$140,259.94)	\$288,038.96
October - 2021	318	34	50	\$41,273,661.96	\$26,537,318.42	\$67,810,980.38	(11)	(17)	(1)	\$387,615.58	\$1,047,331.60	\$1,434,947.18
September - 2021	329	51	51	\$40,886,046.38	\$25,489,986.82	\$66,376,033.20	1	(2)	7	(\$1,015,326.68)	(\$14,926,877.83)	(\$15,942,204.51)
August - 2021	328	53	44	\$41,901,373.06	\$40,416,864.65	\$82,318,237.71	13	26	23	(\$6,602,301.51)	\$8,714,729.10	\$2,112,427.59
July - 2021	315	27	21	\$48,503,674.57	\$31,702,135.55	\$80,205,810.12	10	(6)	(14)	(\$9,463,560.36)	\$917,883.95	(\$8,545,676.41)



NMPSIA BOARD REPORT

ALL YEARS TOTAL														
OPEN CLAIMS FOR WORKERS' COMPENSATION AS OF October 31, 2023														
SCHOOL DISTRICT	OPEN		RE-OPENED		NEW		CLOSED		RESERVE		PAYMENT		TOTAL	
HISTORY	Chg	Ct	Chg	Ct	Chg	Ct	Chg	Ct	Change	Current	Change	Current	Change	Current
OCTOBER-2023	+74	1,051	+6	41	(7)	284	+28	251	+\$44,721	\$14,166,358.01	+\$559,806	\$49,256,175.64	+\$604,527	\$ 63,422,533.65
SEPTEMBER-2023	+103	977	+16	35	(17)	291	(65)	223	+\$126,044	\$14,121,637.30	+\$294,077	\$48,696,369.34	+\$420,121	\$ 62,818,006.64
HISTORY	OPEN		RE-OPENED		NEW		CLOSED		RESERVE		PAYMENT		TOTAL	
HISTORY	Chg	Ct	Chg	Ct	Chg	Ct	Chg	Ct	Change	Current	Change	Current	Change	Current
OCTOBER-2023	+74	1,051	+6	41	(7)	284	+28	251	+\$44,721	\$14,166,358.01	+\$559,806	\$49,256,175.64	+\$604,527	\$ 63,422,533.65
SEPTEMBER-2023	+103	977	+16	35	(17)	291	(65)	223	+\$126,044	\$14,121,637.30	+\$294,077	\$48,696,369.34	+\$420,121	\$ 62,818,006.64
AUGUST-2023	+39	874	+1	19	+245	308	+127	288	+\$132,605	\$13,995,593.65	+\$431,710	\$48,402,292.11	+\$564,315	\$ 62,397,885.76
JULY-2023	(80)	835	(21)	18	(26)	63	(15)	161	(\$262,929)	\$13,862,988.41	(\$143,520)	\$47,970,582.09	(\$406,449)	\$ 61,833,570.50
JUNE-2023	(48)	915	+18	39	(171)	89	(100)	176	(\$379,803)	\$14,125,916.93	(\$219,030)	\$48,114,102.48	(\$598,832)	\$ 62,240,019.41
MAY-2023	+5	963	(3)	21	+12	260	+32	276	+\$68,789	\$14,505,719.52	+\$573,316	\$48,333,132.36	+\$642,104	\$ 62,838,851.88
APRIL-2023	+28	958	(2)	24	+42	248	(20)	244	+\$208,786	\$14,436,930.86	(\$167,817)	\$47,759,816.67	+\$40,969	\$ 62,196,747.53
MARCH-2023	(32)	930	+0	26	(98)	206	(44)	264	+\$324,401	\$14,228,144.59	+\$65,950	\$47,927,633.81	+\$390,351	\$ 62,155,778.40
FEBRUARY-2023	+22	962	+4	26	+92	304	+53	308	+\$152,151	\$13,903,743.67	(\$6,557)	\$47,861,683.74	+\$145,594	\$ 61,765,427.41
JANUARY-2023	(21)	940	(9)	22	+58	212	+54	255	(\$160,549)	\$13,751,592.21	(\$150,749)	\$47,868,241.18	(\$311,299)	\$ 61,619,833.39
DECEMBER-2022	(16)	961	+0	31	(39)	154	(34)	201	(\$67,403)	\$13,912,141.54	+\$336,936	\$48,018,990.62	+\$269,533	\$ 61,931,132.16
NOVEMBER-2022	(11)	977	+6	31	(73)	193	(14)	235	+\$183,112	\$13,979,544.16	+\$140,739	\$47,682,054.64	+\$323,851	\$ 61,661,598.80
OCTOBER-2022	+42	988	(4)	25	(14)	266	(12)	249	+\$23,698	\$13,796,432.07	+\$495,740	\$47,541,316.10	+\$519,438	\$ 61,337,748.17
SEPTEMBER-2022	+48	946	+8	29	+31	280	+5	261	+\$113,539	\$13,772,734.44	(\$36,008)	\$47,045,575.78	+\$77,531	\$ 60,818,310.22
AUGUST-2022	+14	898	+7	21	+191	249	+123	256	+\$245,756	\$13,659,195.34	(\$176,954)	\$47,081,584.06	+\$68,802	\$ 60,740,779.40
JULY-2022	(61)	884	(18)	14	(35)	58	(7)	133	(\$548,564)	\$13,413,439.70	(\$1,038,108)	\$47,258,537.68	(\$1,586,672)	\$ 60,671,977.38
JUNE-2022	(15)	945	+10	32	(114)	93	(59)	140	(\$344,886)	\$13,962,003.26	+\$54,290	\$48,296,645.97	(\$290,596)	\$ 62,258,649.23
MAY-2022	+30	960	(1)	22	+29	207	+18	199	(\$24,133)	\$14,306,889.60	+\$353,763	\$48,242,355.49	+\$329,630	\$ 62,549,245.09
APRIL-2022	+20	930	+1	23	(47)	178	(24)	181	(\$354,710)	\$14,331,022.70	+\$398,883	\$47,888,592.21	+\$44,173	\$ 62,219,614.91
MARCH-2022	+42	910	+7	22	+59	225	+26	205	+\$27,833	\$14,685,732.34	(\$404,683)	\$47,489,709.58	(\$376,850)	\$ 62,175,441.92
FEBRUARY-2022	+2	868	+0	15	+13	166	+10	179	+\$168,625	\$14,657,898.88	(\$178,556)	\$47,894,392.95	(\$9,932)	\$ 62,552,291.83
JANUARY-2022	(1)	866	+2	15	+52	153	(1)	169	+\$204,865	\$14,489,274.20	(\$236,518)	\$48,072,949.17	(\$31,653)	\$ 62,562,223.37




NMPSIA BOARD REPORT

ALL YEARS TOTAL														
OPEN CLAIMS FOR WORKERS' COMPENSATION AS OF October 31, 2023														
CHARTER SCHOOL	OPEN		RE-OPENED		NEW		CLOSED		RESERVE		PAYMENT		TOTAL	
	Chg	Ct	Chg	Ct	Chg	Ct	Chg	Ct	Change	Current	Change	Current	Change	Current
HISTORY														
OCTOBER-2023	+7	71	+0	1	+5	15	+7	9	+\$24,691	\$ 909,448.54	+\$59,999	\$ 1,943,518.67	+\$84,690	\$2,852,967.21
SEPTEMBER-2023	+9	64	+1	1	(3)	10	(17)	2	+\$3,307	\$ 884,757.52	(\$49,422)	\$ 1,883,519.62	(\$46,114)	\$2,768,277.14
CHARTER SCHOOL	OPEN		RE-OPENED		NEW		CLOSED		RESERVE		PAYMENT		TOTAL	
HISTORY	Chg	Ct	Chg	Ct	Chg	Ct	Chg	Ct	Change	Current	Change	Current	Change	Current
OCTOBER-2023	+7	71	+0	1	+5	15	+7	9	+\$24,691	\$ 909,448.54	+\$59,999	\$ 1,943,518.67	+\$84,690	\$2,852,967.21
SEPTEMBER-2023	+9	64	+1	1	(3)	10	(17)	2	+\$3,307	\$ 884,757.52	(\$49,422)	\$ 1,883,519.62	(\$46,114)	\$2,768,277.14
AUGUST-2023	(6)	55	(2)	0	+7	13	+7	19	+\$21,606	\$ 881,450.21	+\$1,463	\$ 1,932,941.30	+\$23,069	\$2,814,391.51
JULY-2023	(4)	61	(1)	2	(2)	6	(2)	12	+\$13,628	\$ 859,844.44	+\$42,236	\$ 1,931,478.22	+\$55,864	\$2,791,322.66
JUNE-2023	(3)	65	+2	3	(1)	8	+4	14	(\$27,164)	\$ 846,216.38	+\$45,031	\$ 1,889,241.82	+\$17,867	\$2,735,458.20
MAY-2023	+0	68	(4)	1	(10)	9	+1	10	+\$25,907	\$ 873,380.47	(\$114,553)	\$ 1,844,210.43	(\$88,646)	\$2,717,590.90
APRIL-2023	+15	68	+5	5	+6	19	+0	9	+\$81,809	\$ 847,473.20	(\$57,929)	\$ 1,958,763.70	+\$23,881	\$2,806,236.90
MARCH-2023	+4	53	(1)	0	+1	13	(1)	9	+\$30,263	\$ 765,663.80	+\$37,841	\$ 2,016,692.49	+\$68,104	\$2,782,356.29
FEBRUARY-2023	+3	49	+0	1	+5	12	(1)	10	+\$7,382	\$ 735,400.88	+\$37,993	\$ 1,978,851.75	+\$45,375	\$2,714,252.63
JANUARY-2023	(3)	46	(1)	1	+0	7	+4	11	(\$22,403)	\$ 728,018.79	(\$34,573)	\$ 1,940,858.92	(\$56,976)	\$2,668,877.71
DECEMBER-2022	+2	49	+2	2	(1)	7	(5)	7	(\$9,378)	\$ 750,421.36	+\$27,437	\$ 1,975,432.31	+\$18,059	\$2,725,853.67
NOVEMBER-2022	(4)	47	+0	0	(3)	8	+5	12	(\$21,224)	\$ 759,799.35	+\$1,554	\$ 1,947,995.10	(\$19,670)	\$2,707,794.45
OCTOBER-2022	+4	51	(2)	0	+1	11	(3)	7	+\$3,404	\$ 781,023.81	+\$37,302	\$ 1,946,440.84	+\$40,706	\$2,727,464.65
SEPTEMBER-2022	+2	47	+2	2	+1	10	+2	10	(\$31,777)	\$ 777,620.22	+\$48,599	\$ 1,909,138.41	+\$16,822	\$2,686,758.63
AUGUST-2022	+1	45	(1)	0	+3	9	(2)	8	+\$13,656	\$ 809,397.01	(\$105,737)	\$ 1,860,539.91	(\$92,081)	\$2,669,936.92
JULY-2022	(3)	44	+0	1	+4	6	+3	10	+\$6,248	\$ 795,741.44	+\$9,746	\$ 1,966,276.84	+\$15,995	\$2,762,018.28
JUNE-2022	(4)	47	+1	1	(9)	2	(7)	7	(\$43,681)	\$ 789,493.43	+\$29,740	\$ 1,956,530.34	(\$13,941)	\$2,746,023.77
MAY-2022	(3)	51	+0	0	+1	11	+10	14	(\$29,616)	\$ 833,174.56	+\$44,892	\$ 1,926,790.51	+\$15,277	\$2,759,965.07
APRIL-2022	+6	54	(2)	0	(6)	10	(5)	4	(\$68,886)	\$ 862,790.36	+\$168,297	\$ 1,881,898.08	+\$99,410	\$2,744,688.44
MARCH-2022	+9	48	+2	2	+11	16	(1)	9	+\$657	\$ 931,676.51	+\$105,793	\$ 1,713,601.47	+\$106,449	\$2,645,277.98
FEBRUARY-2022	(5)	39	(1)	0	+0	5	+6	10	(\$10,262)	\$ 931,019.99	+\$9,860	\$ 1,607,808.58	(\$402)	\$2,538,828.57
JANUARY-2022	+2	44	+0	1	+1	5	(2)	4	(\$57,788)	\$ 941,281.61	+\$15,719	\$ 1,597,948.81	(\$42,069)	\$2,539,230.42
DECEMBER-2021	(1)	42	+1	1	(5)	4	(1)	6	+\$372,644	\$ 999,069.99	+\$11,921	\$ 1,582,229.46	+\$384,565	\$2,581,299.45
NOVEMBER-2021	+2	43	(1)	0	(1)	9	(1)	7	+\$78,324	\$ 626,426.25	(\$25,354)	\$ 1,570,308.41	+\$52,971	\$2,196,734.66
OCTOBER-2021	+3	41	+1	1	+3	10	+5	8	(\$27,115)	\$ 548,101.87	+\$28,569	\$ 1,595,662.06	+\$1,454	\$2,143,763.93
SEPTEMBER-2021	+4	38	+0	0	+0	7	+0	3	(\$14,313)	\$ 575,216.83	+\$44,220	\$ 1,567,093.53	+\$29,907	\$2,142,310.36
AUGUST-2021	+4	34	+0	0	+5	7	+1	3	(\$37,112)	\$ 589,529.88	+\$93,512	\$ 1,522,873.45	+\$56,401	\$2,112,403.33
JULY-2021	+0	30	(2)	0	(1)	2	+0	2	+\$137	\$ 626,641.48	+\$54,157	\$ 1,429,361.01	+\$54,294	\$2,056,002.49
JUNE-2021	+3	30	+1	2	+1	3	+1	2	+\$25,924	\$ 626,504.44	(\$241,619)	\$ 1,375,203.90	(\$215,694)	\$2,001,708.34
MAY-2021	+2	27	+1	1	(8)	2	(7)	1	(\$236,571)	\$ 600,580.03	+\$270,654	\$ 1,616,822.49	+\$34,082	\$2,217,402.52
APRIL-2021	+2	25	(1)	0	+9	10	+6	8	+\$5,731	\$ 837,151.09	(\$21,219)	\$ 1,346,168.99	(\$15,488)	\$2,183,320.08
MARCH-2021	+0	23	+1	1	+0	1	(1)	2	(\$21,294)	\$ 831,419.61	(\$28,199)	\$ 1,367,388.38	(\$49,493)	\$2,198,807.99
FEBRUARY-2021	(2)	23	(1)	0	+1	1	+1	3	(\$50,003)	\$ 852,714.04	+\$33,083	\$ 1,395,586.97	(\$16,921)	\$2,248,301.01
JANUARY-2021	(1)	25	+1	1	(3)	0	(3)	2	(\$12,366)	\$ 902,717.50	+\$21,800	\$ 1,362,504.31	+\$9,434	\$2,265,221.81


# State of New Mexico Comparison

## Average Cost per Claim



# State of New Mexico Comparison

## Average Cost per Indemnity Claim



# NMPSIA

## Total Claims Indemnity and MO 2019 -2020




# NMPSIA

## Total Claims Indemnity and MO 2020 -2021



# NMPSIA


## Total Claims Indemnity and MO 2021 -2022





# NMPSIA

## Total Claims Indemnity and MO 2022 -2023




# NMPSIA

## Total Claims and Reserves 2019 - 2020

<b>2019 - 2020</b>						
Claim Type	Paid	Out Reserve	Recovered	Total Incur	Claim Count	Cost per Claim
Indemnity	\$5,440,174.77	\$702,680.54	\$3,826.14	\$6,139,029.17	354	\$17,341.89
Medical	\$1,054,662.61	\$5,598.88	\$0.00	\$1,060,261.49	821	\$1,291.43
Totals:	\$6,494,837.38	\$708,279.42	\$3,826.14	\$7,199,290.66	1175	\$6,127.06
<b>2020 - 2021</b>						
Claim Type	Paid	Out Reserve	Recovered	Total Incur	Claim Count	Cost per Claim
Indemnity	\$4,546,664.62	\$928,049.59	\$12,374.39	\$5,462,339.82	262	\$20,848.63
Medical	\$525,228.52	\$0.00	\$0.00	\$525,228.52	432	\$1,215.81
Totals:	\$5,071,893.14	\$928,049.59	\$12,374.39	\$5,987,568.34	694	\$8,627.62
<b>2021 - 2020</b>						
Claim Type	Paid	Out Reserve	Recovered	Total Incur	Claim Count	Cost per Claim
Indemnity	\$5,579,671.43	\$1,874,153.81	\$10,308.86	\$7,443,516.38	320	\$23,260.99
Medical	\$976,546.68	\$39,644.40	\$0.00	\$1,016,191.08	832	\$1,221.38
Totals:	\$6,556,218.11	\$1,913,798.21	\$10,308.86	\$8,459,707.46	1152	\$7,343.50
<b>2022 - 2023</b>						
Claim Type	Paid	Out Reserve	Recovered	Total Incur	Claim Count	Cost per Claim
Indemnity	\$4,437,544.95	\$2,686,540.39	\$0.00	\$7,124,085.34	340	\$20,953.19
Medical	\$848,922.25	\$227,186.92	\$0.00	\$1,076,109.17	1012	\$1,063.35
Totals:	\$5,286,467.20	\$2,913,727.31	\$0.00	\$8,200,194.51	1352	\$6,065.23

## Detailed Incident Type

Incident Family	# of Incidents
Bullying	73
General Concern	48
Alcohol / Drugs	38
Harassment / Intimidation	19
Abuse	15
Inappropriate Conduct	15
Eating Disorder	10
Fight / Assault	10
Violence	9
Sexual Misconduct	8
Suicide Ideation	7
Cutting / Self-Harm	7
Discrimination	7
Anger Issue	4
Fraud / Theft	3
Vandalism	2
Weapons	1
<b># of Incidents</b>	<b>276</b>



NMPSIA Monthly Loss Prevention Abatement Report

October 2023	Total Rec	Total Capital	Total Non-Capital	Corrected Capital	Corrected Non-Capital	Total Corrected
October 2023	149	2	147	0	104	104
<b>Total % Corrected</b>	<b>69.80%</b>	<b>= Total Corrected/Total Recommendations</b>				
<b>% Corrected Capital</b>	<b>0.00%</b>	<b>= Corrected Capital/Total Capital</b>				
<b>% Corrected Non-Capital</b>	<b>70.75%</b>	<b>= Corrected Non-Capital/Total Non-Capital</b>				